46 results on '"EIT Health"'
Search Results
2. Efficacy of the echOpen Device to Detect Pyelocaliceal Dilation and Hepatic Steatosis (CLIN-ECHO-II)
- Author
-
ECHOPEN and EIT Health
- Published
- 2024
3. FrAilty Care and wEll-funcTion in Community Dwelling Older Adults (FACET)
- Author
-
EIT Health and Marco Arkesteijn, Lecturer in Sport and Exercise Biomechanics
- Published
- 2024
4. Evaluation of a Computerized Complex Instrumental Activities of Daily Living Marker (NMI) (AltoidaML)
- Author
-
Greek Alzheimer's Association and Related Disorders, University of Roma La Sapienza, IRCCS Centro San Giovanni di Dio Fatebenefratelli, Neuromed IRCCS, Scripps Health, Global Brain Health Institute (GBHI), Takeda Pharmaceuticals International, Inc., Research Center on Computational Biomarkers (RCCBM), BiHELab - Bioinformatics and Human Electrophysiology Lab, Fundacion Clinic per a la Recerca Biomédica, University of Dublin, Trinity College, University of Barcelona, EIT Health, Klinik Hirslanden, Zurich, and Center for BrainHealth - The University of Texas at Dallas
- Published
- 2024
5. Computed Tomography-Guided Catheter Ablation for Ventricular Tachycardia (InEurHeart)
- Author
-
EIT Health
- Published
- 2024
6. AMR-DetecTool for the Diagnostic of MDR Bacterial Infections (AMR DetecTool)
- Author
-
EIT Health, NG Biotech, and Commissariat A L'energie Atomique
- Published
- 2023
7. Investigating Bone Cement With or Without Inossia™ Cement Softener for Vertebral Compression Fractures (SOFTBONE)
- Author
-
EIT Health and Uppsala University
- Published
- 2023
8. Efficacy of the echOpen Device to Identify Effusion and to Detect Basilic Vein (CLIN-ECHO-I)
- Author
-
ECHOPEN and EIT Health
- Published
- 2022
9. Trimodal Prehabilitation in Patients Undergoing Elective Surgery
- Author
-
University Clinical Centre, Gdansk and EIT Health
- Published
- 2021
10. Activating Older People After a Hip Fracture (ActiveHip)
- Author
-
Amgen, Institut de formació contínua - IL3, University of Barcelona, Fundación Pública Andaluza para la Investigación Biomédica Andalucía Oriental, EIT Health, Biohealth Research Institute in Granada (ibs.GRANADA), and Patrocinio Ariza Vega, Principal investigator
- Published
- 2021
11. Patient Empowerment for Major Surgery Preparation @ Home (Paprika)
- Author
-
EIT Health, Hospital Clinic of Barcelona, Universitätsklinikum Köln, and University Clinical Centre, Gdansk
- Published
- 2021
12. Non-invasive Estimation of Atrial Fibrillation Driver Position With Convolutional Neural Networks and Body Surface Potentials
- Author
-
Universitat Politècnica de València. Departamento de Ingeniería Electrónica - Departament d'Enginyeria Electrònica, EIT Health, Comunidad de Madrid, INSTITUTO DE SALUD CARLOS III, Agencia Estatal de Investigación, European Regional Development Fund, COMISION DE LAS COMUNIDADES EUROPEA, Ministerio de Ciencia, Innovación y Universidades, Cámara-Vázquez, Miguel Ángel, Hernández-Romero, Ismael, Morgado-Reyes, Eduardo, Guillem Sánchez, María Salud, Climent, Andreu M., Barquero-Pérez, Oscar, Universitat Politècnica de València. Departamento de Ingeniería Electrónica - Departament d'Enginyeria Electrònica, EIT Health, Comunidad de Madrid, INSTITUTO DE SALUD CARLOS III, Agencia Estatal de Investigación, European Regional Development Fund, COMISION DE LAS COMUNIDADES EUROPEA, Ministerio de Ciencia, Innovación y Universidades, Cámara-Vázquez, Miguel Ángel, Hernández-Romero, Ismael, Morgado-Reyes, Eduardo, Guillem Sánchez, María Salud, Climent, Andreu M., and Barquero-Pérez, Oscar
- Abstract
[EN] Atrial fibrillation (AF) is characterized by complex and irregular propagation patterns, and AF onset locations and drivers responsible for its perpetuation are the main targets for ablation procedures. ECG imaging (ECGI) has been demonstrated as a promising tool to identify AF drivers and guide ablation procedures, being able to reconstruct the electrophysiological activity on the heart surface by using a non-invasive recording of body surface potentials (BSP). However, the inverse problem of ECGI is ill-posed, and it requires accurate mathematical modeling of both atria and torso, mainly from CT or MR images. Several deep learning-based methods have been proposed to detect AF, but most of the AF-based studies do not include the estimation of ablation targets. In this study, we propose to model the location of AF drivers from BSP as a supervised classification problem using convolutional neural networks (CNN). Accuracy in the test set ranged between 0.75 (SNR = 5 dB) and 0.93 (SNR = 20 dB upward) when assuming time independence, but it worsened to 0.52 or lower when dividing AF models into blocks. Therefore, CNN could be a robust method that could help to non-invasively identify target regions for ablation in AF by using body surface potential mapping, avoiding the use of ECGI.
- Published
- 2021
13. Electrocardiographic Imaging for Atrial Fibrillation: A Perspective From Computer Models and Animal Experiments to Clinical Value
- Author
-
Universitat Politècnica de València. Departamento de Ingeniería Electrónica - Departament d'Enginyeria Electrònica, EIT Health, European Commission, Generalitat Valenciana, British Heart Foundation, Instituto de Salud Carlos III, Agencia Estatal de Investigación, European Regional Development Fund, National Institutes of Health, EEUU, Medical Research Council, Reino Unido, National Heart, Lung, and Blood Institute, EEUU, Netherlands Organization for Scientific Research, Ministerio de Ciencia, Innovación y Universidades, National Institute of General Medical Sciences, EEUU, Fundação de Amparo à Pesquisa do Estado de São Paulo, Centro de Investigación Biomédica en Red Enfermedades Cardiovasculares, Salinet, Joao, Molero-Alabau, Rubén, Schlindwein, Fernando S., Karel, Joël, Rodrigo, Miguel, Rojo-Álvarez, José Luis, Berenfeld, Omer, Climent, Andreu M., Zenger, Brian, Vanheusden, Frederique, Siles Paredes, Jimena Gabriela, MacLeod, Rob, Atienza, Felipe, Guillem Sánchez, María Salud, Cluitmans, Matthijs, Bonizzi, Pietro, Universitat Politècnica de València. Departamento de Ingeniería Electrónica - Departament d'Enginyeria Electrònica, EIT Health, European Commission, Generalitat Valenciana, British Heart Foundation, Instituto de Salud Carlos III, Agencia Estatal de Investigación, European Regional Development Fund, National Institutes of Health, EEUU, Medical Research Council, Reino Unido, National Heart, Lung, and Blood Institute, EEUU, Netherlands Organization for Scientific Research, Ministerio de Ciencia, Innovación y Universidades, National Institute of General Medical Sciences, EEUU, Fundação de Amparo à Pesquisa do Estado de São Paulo, Centro de Investigación Biomédica en Red Enfermedades Cardiovasculares, Salinet, Joao, Molero-Alabau, Rubén, Schlindwein, Fernando S., Karel, Joël, Rodrigo, Miguel, Rojo-Álvarez, José Luis, Berenfeld, Omer, Climent, Andreu M., Zenger, Brian, Vanheusden, Frederique, Siles Paredes, Jimena Gabriela, MacLeod, Rob, Atienza, Felipe, Guillem Sánchez, María Salud, Cluitmans, Matthijs, and Bonizzi, Pietro
- Abstract
[EN] Electrocardiographic imaging (ECGI) is a technique to reconstruct non-invasively the electrical activity on the heart surface from body-surface potential recordings and geometric information of the torso and the heart. ECGI has shown scientific and clinical value when used to characterize and treat both atrial and ventricular arrhythmias. Regarding atrial fibrillation (AF), the characterization of the electrical propagation and the underlying substrate favoring AF is inherently more challenging than for ventricular arrhythmias, due to the progressive and heterogeneous nature of the disease and its manifestation, the small volume and wall thickness of the atria, and the relatively large role of microstructural abnormalities in AF. At the same time, ECGI has the advantage over other mapping technologies of allowing a global characterization of atrial electrical activity at every atrial beat and non-invasively. However, since ECGI is time-consuming and costly and the use of electrical mapping to guide AF ablation is still not fully established, the clinical value of ECGI for AF is still under assessment. Nonetheless, AF is known to be the manifestation of a complex interaction between electrical and structural abnormalities and therefore, true electro-anatomical-structural imaging may elucidate important key factors of AF development, progression, and treatment. Therefore, it is paramount to identify which clinical questions could be successfully addressed by ECGI when it comes to AF characterization and treatment, and which questions may be beyond its technical limitations. In this manuscript we review the questions that researchers have tried to address on the use of ECGI for AF characterization and treatment guidance (for example, localization of AF triggers and sustaining mechanisms), and we discuss the technological requirements and validation. We address experimental and clinical results, limitations, and future challenges for fruitful application of ECGI fo
- Published
- 2021
14. Noninvasive Assessment of Complexity of Atrial Fibrillation Correlation With Contact Mapping and Impact of Ablation
- Author
-
Universitat Politècnica de València. Instituto Universitario de Telecomunicación y Aplicaciones Multimedia - Institut Universitari de Telecomunicacions i Aplicacions Multimèdia, Universitat Politècnica de València. Departamento de Ingeniería Electrónica - Departament d'Enginyeria Electrònica, EIT Health, Generalitat Valenciana, Instituto de Salud Carlos III, European Regional Development Fund, National Institutes of Health, EEUU, Ministerio de Economía y Competitividad, RODRIGO BORT, MIGUEL, Martínez Climent, Batiste Andreu, Hernández-Romero, Ismael, Liberos Mascarell, Alejandro, Baykaner, Tina, Rogers, Albert J., Alhusseini, Mahmood, Wang, Paul J., Fernández-Avilés, Francisco, Guillem Sánchez, María Salud, Narayan, Sanjiv M., Atienza, Felipe, Universitat Politècnica de València. Instituto Universitario de Telecomunicación y Aplicaciones Multimedia - Institut Universitari de Telecomunicacions i Aplicacions Multimèdia, Universitat Politècnica de València. Departamento de Ingeniería Electrónica - Departament d'Enginyeria Electrònica, EIT Health, Generalitat Valenciana, Instituto de Salud Carlos III, European Regional Development Fund, National Institutes of Health, EEUU, Ministerio de Economía y Competitividad, RODRIGO BORT, MIGUEL, Martínez Climent, Batiste Andreu, Hernández-Romero, Ismael, Liberos Mascarell, Alejandro, Baykaner, Tina, Rogers, Albert J., Alhusseini, Mahmood, Wang, Paul J., Fernández-Avilés, Francisco, Guillem Sánchez, María Salud, Narayan, Sanjiv M., and Atienza, Felipe
- Abstract
[EN] Background: It is difficult to noninvasively phenotype atrial fibrillation (AF) in a way that reflects clinical end points such as response to therapy. We set out to map electrical patterns of disorganization and regions of reentrant activity in AF from the body surface using electrocardiographic imaging, calibrated to panoramic intracardiac recordings and referenced to AF termination by ablation. Methods: Bi-atrial intracardiac electrograms of 47 patients with AF at ablation (30 persistent, 29 male, 63 +/- 9 years) were recorded with 64-pole basket catheters and simultaneous 57-lead body surface ECGs. Atrial epicardial electrical activity was reconstructed and organized sites were invasively and noninvasively tracked in 3-dimension using phase singularity. In a subset of 17 patients, sites of AF organization were targeted for ablation. Results: Body surface mapping showed greater AF organization near intracardially detected drivers than elsewhere, both in phase singularity density (2.3 +/- 2.1 versus 1.9 +/- 1.6; P=0.02) and number of drivers (3.2 +/- 2.3 versus 2.7 +/- 1.7; P=0.02). Complexity, defined as the number of stable AF reentrant sites, was concordant between noninvasive and invasive methods (r(2)=0.5; CC=0.71). In the subset receiving targeted ablation, AF complexity showed lower values in those in whom AF terminated than those in whom AF did not terminate (P<0.01). Conclusions: AF complexity tracked noninvasively correlates well with organized and disorganized regions detected by panoramic intracardiac mapping and correlates with the acute outcome by ablation. This approach may assist in bedside monitoring of therapy or in improving the efficacy of ongoing ablation procedures.
- Published
- 2020
15. Automatic quality electrogram assessment improves phase-based reentrant activity identification in atrial fibrillation
- Author
-
Universitat Politècnica de València. Departamento de Ingeniería Electrónica - Departament d'Enginyeria Electrònica, Universitat Politècnica de València. Instituto Universitario de Telecomunicación y Aplicaciones Multimedia - Institut Universitari de Telecomunicacions i Aplicacions Multimèdia, Nvidia, EIT Health, Generalitat Valenciana, Instituto de Salud Carlos III, European Regional Development Fund, National Institutes of Health, EEUU, Ministerio de Economía y Competitividad, Costoya-Sánchez, Alejandro, Climent, Andreu M., Hernández-Romero, Ismael, Liberos Mascarell, Alejandro, Fernández-Avilés, Francisco, Narayan, Sanjiv M., Atienza, Felipe, Guillem Sánchez, María Salud, RODRIGO BORT, MIGUEL, Universitat Politècnica de València. Departamento de Ingeniería Electrónica - Departament d'Enginyeria Electrònica, Universitat Politècnica de València. Instituto Universitario de Telecomunicación y Aplicaciones Multimedia - Institut Universitari de Telecomunicacions i Aplicacions Multimèdia, Nvidia, EIT Health, Generalitat Valenciana, Instituto de Salud Carlos III, European Regional Development Fund, National Institutes of Health, EEUU, Ministerio de Economía y Competitividad, Costoya-Sánchez, Alejandro, Climent, Andreu M., Hernández-Romero, Ismael, Liberos Mascarell, Alejandro, Fernández-Avilés, Francisco, Narayan, Sanjiv M., Atienza, Felipe, Guillem Sánchez, María Salud, and RODRIGO BORT, MIGUEL
- Abstract
[EN] Identification of reentrant activity driving atrial fibrillation (AF) is increasingly important to ablative therapies. The goal of this work is to study how the automatically-classified quality of the electrograms (EGMs) affects reentrant AF driver localization. EGMs from 259 AF episodes obtained from 29 AF patients were recorded using 64-poles basket catheters and were manually classified according to their quality. An algorithm capable of identifying signal quality was developed using time and spectral domain parameters. Electrical reentries were identified in 3D phase maps using phase transform and were compared with those obtained with a 2D activation-based method. Effect of EGM quality was studied by discarding 3D phase reentries detected in regions with low-quality EGMs. Removal of reentries identified by 3D phase analysis in regions with low-quality EGMs improved its performance, increasing the area under the ROC curve (AUC) from 0.69 to 0.80. The EGMs quality classification algorithm showed an accurate performance for EGM classification (AUC 0.94) and reentry detection (AUC 0.80). Automatic classification of EGM quality based on time and spectral signal parameters is feasible and accurate, avoiding the manual labelling. Discard of reentries identified in regions with automatically-detected poor-quality EGMs improved the specificity of the 3D phase-based method for AF driver identification.
- Published
- 2020
16. Optical imaging of voltage and calcium in isolated hearts: Linking spatiotemporal heterogeneities and ventricular fibrillation initiation
- Author
-
Universitat Politècnica de València. Departamento de Ingeniería Electrónica - Departament d'Enginyeria Electrònica, Universitat Politècnica de València. Instituto Universitario de Telecomunicación y Aplicaciones Multimedia - Institut Universitari de Telecomunicacions i Aplicacions Multimèdia, EIT Health, Generalitat Valenciana, Instituto de Salud Carlos III, European Regional Development Fund, Ministerio de Economía y Competitividad, Centro de Investigación Biomédica en Red Enfermedades Cardiovasculares, Hernández-Romero, Ismael, Guillem Sánchez, María Salud, Figuera, Carlos, Atienza, Felipe, Fernández-Avilés, Francisco, Martínez Climent, Batiste Andreu, Universitat Politècnica de València. Departamento de Ingeniería Electrónica - Departament d'Enginyeria Electrònica, Universitat Politècnica de València. Instituto Universitario de Telecomunicación y Aplicaciones Multimedia - Institut Universitari de Telecomunicacions i Aplicacions Multimèdia, EIT Health, Generalitat Valenciana, Instituto de Salud Carlos III, European Regional Development Fund, Ministerio de Economía y Competitividad, Centro de Investigación Biomédica en Red Enfermedades Cardiovasculares, Hernández-Romero, Ismael, Guillem Sánchez, María Salud, Figuera, Carlos, Atienza, Felipe, Fernández-Avilés, Francisco, and Martínez Climent, Batiste Andreu
- Abstract
[EN] Background Alternans have been associated with the development of ventricular fibrillation and its control has been proposed as antiarrhythmic strategy. However, cardiac arrhythmias are a spatiotemporal phenomenon in which multiple factors are involved (e.g. calcium and voltage spatial alternans or heterogeneous conduction velocity) and how an antiarrhythmic drug modifies these factors is poorly understood. Objective The objective of the present study is to evaluate the relation between spatial electrophysiological properties (i.e. spatial discordant alternans and conduction velocity) and the induction of ventricular fibrillation (VF) when a calcium blocker is applied. Methods The mechanisms of initiation of VF were studied by simultaneous epicardial voltage and calcium optical mapping in isolated rabbit hearts using an incremental fast pacing protocol. The additional value of analyzing spatial phenomena in the generation of unidirectional blocks and reentries as precursors of VF was depicted. Specifically, the role of action potential duration (APD), calcium transients (CaT), spatial alternans and conduction velocity in the initiation of VF was evaluated during basal conditions and after the administration of verapamil. Results Our results enhance the relation between (1) calcium spatial alternans and (2) slow conduction velocities with the dynamic creation of unidirectional blocks that allowed the induction of VF. In fact, the administration of verapamil demonstrated that calcium and not voltage spatial alternans were the main responsible for VF induction. Conclusions VF induction at high activation rates was linked with the concurrence of a low conduction velocity and high magnitude of calcium alternans, but not necessarily related with increases of APD. Verapamil can postpone the development of cardiac alternans and the apparition of ventricular arrhythmias.
- Published
- 2019
17. ONCOhabitats: A system for glioblastoma heterogeneity assessment through MRI
- Author
-
Universitat Politècnica de València. Departamento de Física Aplicada - Departament de Física Aplicada, Universitat Politècnica de València, EIT Health, Ministerio de Economía y Empresa, Fundació Bancària Caixa d'Estalvis i Pensions de Barcelona, Ministerio de Economía y Competitividad, Juan -Albarracín, Javier, Fuster García, Elíes, García-Ferrando, Germán Adrián, Garcia-Gomez, Juan M, Universitat Politècnica de València. Departamento de Física Aplicada - Departament de Física Aplicada, Universitat Politècnica de València, EIT Health, Ministerio de Economía y Empresa, Fundació Bancària Caixa d'Estalvis i Pensions de Barcelona, Ministerio de Economía y Competitividad, Juan -Albarracín, Javier, Fuster García, Elíes, García-Ferrando, Germán Adrián, and Garcia-Gomez, Juan M
- Abstract
[EN] Background: Neuroimaging analysis is currently crucial for an early assessment of glioblastoma, to help improving treatment and tumor follow-up. To this end, multiple functional and morphological MRI sequences are usually employed, requiring the development of automated tools capable to extract the relevant information from these sources. In this work we present ONCOhabitats (https://www.oncohabitats.upv.es): an online open access system for glioblastoma analysis based on MRI data. Methods: ONCOhabitats provides two main services for untreated glioblastomas: (1) malignant tissue segmentation, and (2) vascular heterogeneity assessment of the tumor. The segmentation service implements a deep patch-wise 3D Convolutional Neural Network with residual connections. The vascular heterogeneity assessment service implements the Hemodynamic Tissue Signature (HTS) method patented in P201431289, which aims to identify habitats within the tumor with early prognostic capabilities. Results: The segmentation service was validated against the BRATS 2017 reference dataset, showing comparable results with current state-of-the-art methods (whole tumor Dice segmentation: 0.89). The vascular heterogeneity assessment service was validated in a retrospective cohort of 50 patients, in a study focused on predicting patient overall survival based on the HTS habitats. Cox proportional hazard regression analysis and Kaplan-Meier survival study showed significant positive correlations (p-value < .05) between the HTS habitats and patient overall survival. ONCOhabitats system also generates radiological reports for each service, including volumetries and perfusion measurements of the different regions of the lesion. Conclusion: ONCOhabitats system provides open-access services for glioblastoma heterogeneity assessment, implementing consolidated state-of-the-art techniques for medical image analysis. Additionally, we also give access to the scientific community to our computational resources, o
- Published
- 2019
18. Temporal Stability of Dominant Frequency as Predictor of Atrial Fibrillation Recurrence
- Author
-
EIT Health, Generalitat Valenciana, Instituto de Salud Carlos III, European Regional Development Fund, Ministerio de Economía y Competitividad, Costoya-Sánchez, Alejandro, Climent, Andreu M., Hernández-Romero, Ismael, Liberos, Alejandro, Fernández-Avilés, Francisco, Narayan, Sanjiv M., Atienza, Felipe, Guillem Sánchez, María Salud, Rodrigo, Miguel, EIT Health, Generalitat Valenciana, Instituto de Salud Carlos III, European Regional Development Fund, Ministerio de Economía y Competitividad, Costoya-Sánchez, Alejandro, Climent, Andreu M., Hernández-Romero, Ismael, Liberos, Alejandro, Fernández-Avilés, Francisco, Narayan, Sanjiv M., Atienza, Felipe, Guillem Sánchez, María Salud, and Rodrigo, Miguel
- Abstract
[EN] Catheter ablation is one of the main therapies for restoring sinus rhythm in patients with atrial fibrillation (AF), yet AF termination ratios are far from satisfactory. The goal of this work is to study if temporal stability of dominant frequencies (DFs) of electrograms (EGMs) can be used as predictor of AF recurrence. EGMs were recorded from 29 AF patients using 64- pole basket catheters during the ablation procedure. DFs before ablation were obtained for 4-second overlapping fragments of EGM recordings with a 0.4 s shift, and their temporal stability was evaluated for short-term (between 8 and 12 s) and long-term time intervals (>5 min). Patients were classified as AF (N=15) if sinus rhythm was not maintained in a 12-month post-ablation followup, and AF free otherwise (N=14). Significant differences were found in the short-term analysis between AF free and AF patients for the difference between the mode value in DFs (p=0.045), as well as for the long-term analysis for the normalized average between DFs (p=0.028) and the average between DFs (p=0.043). More stable values were found for AF free patients for all statistically significant metrics. Short- and long-term temporal stability of DF values of EGM signals were found to be associated with the 12- month success rate of ablative therapies of AF patients.
- Published
- 2019
19. Automatic Quality Electrogram Assessment Improves Reentrant Activity Identification in Atrial Fibrillation
- Author
-
EIT Health, Generalitat Valenciana, Instituto de Salud Carlos III, European Regional Development Fund, Ministerio de Economía y Competitividad, Costoya-Sánchez, Alejandro, Climent, Andreu M., Hernández-Romero, Ismael, Liberos, Alejandro, Fernández-Avilés, Francisco, Narayan, Sanjiv M., Atienza, Felipe, Guillem Sánchez, María Salud, Rodrigo, Miguel, EIT Health, Generalitat Valenciana, Instituto de Salud Carlos III, European Regional Development Fund, Ministerio de Economía y Competitividad, Costoya-Sánchez, Alejandro, Climent, Andreu M., Hernández-Romero, Ismael, Liberos, Alejandro, Fernández-Avilés, Francisco, Narayan, Sanjiv M., Atienza, Felipe, Guillem Sánchez, María Salud, and Rodrigo, Miguel
- Abstract
[EN] Location of reentrant electrical activity responsible for driving atrial fibrillation (AF) is key to ablative therapies. The aim of this work is to study the effect of the quality of the electrograms (EGMs) used for 3D phase analysis on reentrant activity identification, as well as to develop an algorithm capable of automatically identifying lowquality signals. EGMs signals from 259 episodes obtained from 29 AF patients were recorded using 64-electrode basket catheters. Low-quality EGMs were manually identified. Reentrant activity was identified in 3D phase maps and provided an area under the ROC curve (AUC) of 0.69 when compared to a 2D activation-based method. Reentries located in regions with poor-quality EGMs were then removed, increasing the AUC to 0.80. The EGM classification algorithm showed a similar performance both for low-quality EGM identification (sensitivity 0.91 and specificity 0.80) and for reentrant activity location with 3D phase analysis (AUC 0.80). Discard of reentrant activity identified in regions where EGMs showed low quality significantly improved the specificity of the 3D phase analysis. Besides, EGMs classification according to their quality proved to be possible using time and spectral domain parameters.
- Published
- 2019
20. Non-Invasive Electrophysiological Mapping Entropy Predicts Atrial Fibrillation Ablation Efficacy Better Than Clinical Characteristics
- Author
-
Universitat Politècnica de València. Departamento de Ingeniería Electrónica - Departament d'Enginyeria Electrònica, EIT Health, Instituto de Salud Carlos III, European Regional Development Fund, Ministerio de Economía y Competitividad, De la Nava, A. S., Fabregat, M. C., Rodrigo, M., Hernández, I., Liberos, A., Fernández-Avilés, F., Guillem Sánchez, María Salud, Atienza, F., Climent, Andreu M., Universitat Politècnica de València. Departamento de Ingeniería Electrónica - Departament d'Enginyeria Electrònica, EIT Health, Instituto de Salud Carlos III, European Regional Development Fund, Ministerio de Economía y Competitividad, De la Nava, A. S., Fabregat, M. C., Rodrigo, M., Hernández, I., Liberos, A., Fernández-Avilés, F., Guillem Sánchez, María Salud, Atienza, F., and Climent, Andreu M.
- Abstract
[EN] Success rate of atrial fibrillation (AF) ablation remains far from satisfactory. In this study, a 6 months AF freedom predictive model based on Fuzzy Entropy of non-invasive body surface potential maps is compared with clinical predictors. The study included 29 patients referred for pulmonary vein isolated catheter ablation procedure. Non-invasive electrocardiographic mapping with 54 ECG electrodes was recorded for all patients during the ablation procedure. Six months follow up was used to evaluate the efficacy of the ablation procedure. Predictions based on non-invasive electrocardiographic mappings during adenosine infusion (accuracy: 90%, AUC: 0.93) showed a clear improvement over standard-of-care clinical parameter models (accuracy: 62.1%, AUC: 0. 54). Our results indicate that measurements of electrophysiological complexity of AF signals could improve the clinical practice by predicting the efficacy of AF ablation procedures.
- Published
- 2019
21. Effects of Geometry in Atrial Fibrillation Markers Obtained With Electrocardiographic Imaging
- Author
-
Universitat Politècnica de València. Departamento de Ingeniería Electrónica - Departament d'Enginyeria Electrònica, EIT Health, Generalitat Valenciana, Instituto de Salud Carlos III, European Regional Development Fund, Ministerio de Economía y Competitividad, Molero-Alabau, Rubén, Climent, Andreu M., Hernández-Romero, Ismael, Liberos, Alejandro, Fernández-Avilés, Francisco, Atienza, Felipe, Guillem Sánchez, María Salud, Rodrigo, Miguel, Universitat Politècnica de València. Departamento de Ingeniería Electrónica - Departament d'Enginyeria Electrònica, EIT Health, Generalitat Valenciana, Instituto de Salud Carlos III, European Regional Development Fund, Ministerio de Economía y Competitividad, Molero-Alabau, Rubén, Climent, Andreu M., Hernández-Romero, Ismael, Liberos, Alejandro, Fernández-Avilés, Francisco, Atienza, Felipe, Guillem Sánchez, María Salud, and Rodrigo, Miguel
- Abstract
[EN] Electrocardiographic imaging (ECGI) can characterise cardiac pathologies such as atrial fibrillation (AF) through specific markers based on frequency or phase analysis. In this study, the effect of the geometry of patients torso and atria in the ECGI resolution is studied. A realistic 3D atrial geometry was located on 30 patient torsos and ECGI signals were calculated for 30 different AF simulations in each torso. Dominant frequency (DF) and reentrant activity analysis were calculated for each scenario. Anatomical and geometrical measurements of each torso (30-80% of variability between patients) and atria were calculated and compared with the errors in the ECGI estimation versus the departing EGM maps. Results show evidences that big chest dimensions worsen the non-invasive calculation of AF markers (p<0.05). Also, higher number of visible electrodes from each atrial region improves ECGI characterization measured as lower DF deviations (0.64±0.26 Hz vs 0.72±0.27 Hz, p<0.05) and higher reentrant activity coincidence (10.1±12.2% vs 3.4±3.4%, p<0.05). Torso and atrial geometry affect the quality of the non-invasive reconstruction of AF markers such as DF or reentrant activity. Knowing the geometrical parameters that worsen non-invasive AF maps may help to measure each detected AF driver reliability.
- Published
- 2019
22. A usability study in patients with stroke using MERLIN, a robotic system based on serious games for upper limb rehabilitation in the home setting
- Author
-
Pablo Casado-Adam, Silvia Guillén-Climent, Manuela Mejías-Ruiz, Fernando Jesús Mayordomo-Riera, Ainara Garzo, María Nieves Muñoz-Alcaraz, Javier Arcas-Ruiz-Ruano, [Guillén-Climent,S, Muñoz-Alcaraz,MN] Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Reina Sofa University Hospital, University of Cordoba, Córdoba, Spain. [Garzo,A, Arcas-Ruiz-Ruano,J] Neurorehabilitation area, Health Division of TECNALIA, Basque Research and Technology Alliance (BRTA), San Sebastián, Spain. [Muñoz-Alcaraz,MN, Casado-Adam,P, Mejías-Ruiz,M, Mayordomo-Riera,FJ] Interlevel Clinical Management Unit of Physical Medicine and Rehabilitation, Reina Sofía University Hospital of Córdoba, Córdoba, Spain. [Muñoz-Alcaraz,MN] Córdoba and Guadalquivir Health District, Andalusia Health Service, Córdoba, Spain. [Mayordomo-Riera,FJ] Department of Applied Physics, Radiology and Physical Medicine, University of Córdoba, Córdoba, Spain., and This research is part of a MERLIN project, which has received funding from EIT Health (Grant no. 20649). EIT Health is supported by the European Institute of Innovation and Technology (EIT), a body of the European Union which receives support from the European Union’s Horizon 2020 Research and innovation programme.
- Subjects
Male ,030506 rehabilitation ,Serious games ,Neurology ,Robot ,medicine.medical_treatment ,Anatomy::Body Regions::Extremities::Upper Extremity [Medical Subject Headings] ,Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings] ,User-Computer Interface ,0302 clinical medicine ,Telerehabilitation ,Medicine ,Stroke ,Persons::Persons::Age Groups::Adult::Aged [Medical Subject Headings] ,Aged, 80 and over ,Rehabilitation ,Information Science::Information Science::Computing Methodologies::Software::User-Computer Interface [Medical Subject Headings] ,Home training ,Anthropology, Education, Sociology and Social Phenomena::Human Activities::Leisure Activities::Recreation::Play and Playthings::Video Games [Medical Subject Headings] ,System usability scale ,Stroke Rehabilitation ,Robotics ,Middle Aged ,Exercise Therapy ,medicine.anatomical_structure ,Patient Satisfaction ,Extremidad superior ,Upper limb ,Female ,0305 other medical science ,Analytical, Diagnostic and Therapeutic Techniques and Equipment::Therapeutics::Physical Therapy Modalities::Exercise Therapy [Medical Subject Headings] ,Diseases::Nervous System Diseases::Central Nervous System Diseases::Brain Diseases::Cerebrovascular Disorders::Stroke [Medical Subject Headings] ,Adult ,Telerrehabilitación ,medicine.medical_specialty ,Upper extremity ,Ejercicio en circuitos ,Modified Ashworth scale ,Check Tags::Male [Medical Subject Headings] ,Health Informatics ,Information Science::Information Science::Computing Methodologies::Artificial Intelligence::Robotics [Medical Subject Headings] ,Neurological rehabilitation ,Accidente cerebrovascular ,Health Care::Health Care Quality, Access, and Evaluation::Delivery of Health Care::Attitude to Health::Patient Acceptance of Health Care::Patient Satisfaction [Medical Subject Headings] ,lcsh:RC321-571 ,03 medical and health sciences ,Humans ,Persons::Persons::Age Groups::Adult [Medical Subject Headings] ,lcsh:Neurosciences. Biological psychiatry. Neuropsychiatry ,Aged ,business.industry ,Research ,Usability ,Persons::Persons::Age Groups::Adult::Middle Aged [Medical Subject Headings] ,Recovery of Function ,medicine.disease ,Phenomena and Processes::Biological Phenomena::Recovery of Function [Medical Subject Headings] ,Video Games ,Check Tags::Female [Medical Subject Headings] ,Persons::Persons::Age Groups::Adult::Aged::Aged, 80 and over [Medical Subject Headings] ,Physical therapy ,Neurorrehabilitación ,business ,030217 neurology & neurosurgery - Abstract
Background Neuroscience and neurotechnology are transforming stroke rehabilitation. Robotic devices, in addition to telerehabilitation, are increasingly being used to train the upper limbs after stroke, and their use at home allows us to extend institutional rehabilitation by increasing and prolonging therapy. The aim of this study is to assess the usability of the MERLIN robotic system based on serious games for upper limb rehabilitation in people with stroke in the home environment. Methods 9 participants with a stroke in three different stages of recovery (subacute, short-term chronic and long-term chronic) with impaired arm/hand function, were recruited to use the MERLIN system for 3 weeks: 1 week training at the Maimonides Biomedical Research Institute of Cordoba (IMIBIC), and 2 weeks at the patients’ homes. To evaluate usability, the System Usability Scale (SUS), Adapted Intrinsic Motivation Inventory (IMI), Quebec User Evaluation of Satisfaction with assistive Technology (QUEST), and the ArmAssist Usability Assessment Questionnaire were used in the post-intervention. Clinical outcomes for upper limb motor function were assessed pre- and post-intervention. Results 9 patients participated in and completed the study. The usability assessment reported a high level of satisfaction: mean SUS score 71.94 % (SD = 16.38), mean QUEST scale 3.81 (SD = 0.38), and mean Adapted IMI score 6.12 (SD = 1.36). The results of the ArmAssist Questionnaire showed an average of 6 out of 7, which indicates that MERLIN is extremely intuitive, easy to learn and easy to use. Regarding clinical assessment, the Fugl-Meyer scores showed moderate improvements from pre- to post-intervention in the total score of motor function (p = 0.002). There were no significant changes in the Modified Ashworth scale outcomes (p = 0.169). Conclusions This usability study indicates that home-based rehabilitation for upper limbs with the MERLIN system is safe, useful, feasible and motivating. Telerehabilitation constitutes a major step forward in the use of intensive rehabilitation at home. Trial registration ClinicalTrials.gov, NCT04405609. Registered 06 January 2020—Retrospectively registered, https://clinicaltrials.gov/ct2/show/NCT04405609
- Published
- 2021
23. Rapid detection of vana/b-producing vancomycin-resistant enterococci using lateral flow immunoassay
- Author
-
Vincent Cattoir, Camille Gonzalez, Duncan Dulac, Sandrine Bernabeu, Laurent Dortet, Laure Boutigny, Delphine Girlich, Marc Plaisance, Saoussen Oueslati, Thierry Naas, Hervé Volland, Stéphanie Simon, Immunologie des maladies virales, auto-immunes, hématologiques et bactériennes (IMVA-HB), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, Médicaments et Technologies pour la Santé (MTS), Université Paris-Saclay-Direction de Recherche Fondamentale (CEA) (DRF (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), CHU Pontchaillou [Rennes], ARN régulateurs bactériens et médecine (BRM), Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), NG Biotech, EIT Health, Agence Nationale de la Recherche, ANR: ANR-10-LABX-33, Institut National de la Santé et de la Recherche Médicale, Inserm: U1184, Université Paris-Saclay, ANR-10-LABX-0033,LERMIT,Research Laboratory on Drugs and Therapeutic Innovation(2010), Jonchère, Laurent, Research Laboratory on Drugs and Therapeutic Innovation - - LERMIT2010 - ANR-10-LABX-0033 - LABX - VALID, Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )-Université de Rennes 1 (UR1), and Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)
- Subjects
Medicine (General) ,VRE ,[SDV]Life Sciences [q-bio] ,Clinical Biochemistry ,Rapid detection ,Article ,Microbiology ,03 medical and health sciences ,Chocolate agar ,chemistry.chemical_compound ,R5-920 ,Medicine ,030304 developmental biology ,Vancomycin resistance ,0303 health sciences ,biology ,030306 microbiology ,business.industry ,Vancomycin-Resistant Enterococci ,Rapid diagnostics ,biochemical phenomena, metabolism, and nutrition ,biology.organism_classification ,bacterial infections and mycoses ,LFIA ,3. Good health ,[SDV] Life Sciences [q-bio] ,Clinical microbiology ,chemistry ,Vancomycin ,Immunochromatography ,business ,Bacteria ,Lateral flow immunoassay ,medicine.drug - Abstract
International audience; Vancomycin-resistant enterococci (VREs) have become one of the most important noso-comial pathogens worldwide, associated with increased treatment costs, prolonged hospital stays and high mortality. Rapid detection is crucial to reduce their spread and prevent infections and outbreaks. The lateral flow immunoassay NG-Test VanB (NG Biotech) was evaluated for the rapid detection of VanB-producing vancomycin-resistant enterococci (VanB-VREs) using 104 well-char-acterized enterococcal isolates. The sensitivity and specificity were both 100% when bacterial cells were grown in the presence of vancomycin used as a VanB inducer. The NG-Test VanB is an effi-cient, rapid and easy to implement assay in clinical microbiology laboratories for the confirmation of VanB-VREs from colonies. Together with the NG-Test VanA, they could replace the already ex-isting tests available for the confirmation of acquired vancomycin resistance in enterococci, especially from selective media or from antibiograms, with 100% sensitivity and specificity. Rapid detection in less than 15 min will result in more efficient management of carriers and infected patients. In addition, these tests may be used for positive blood cultures, given a 3.5 h sub-culturing step on Chocolate agar PolyViteX in the presence of a 5-µg vancomycin disk, which is routinely performed in many clinical microbiology laboratories for every positive blood culture for subsequent MALDI-TOF identification of the growing bacteria.
- Published
- 2021
24. Development and validation of a lateral flow immunoassay for rapid detection of VanA-producing enterococci
- Author
-
Marc Plaisance, Saoussen Oueslati, Thierry Naas, Sandrine Bernabeu, Hervé Volland, Vincent Cattoir, Delphine Girlich, Ducan Dulac, Laurent Dortet, Maxime Laroche, Stéphanie Simon, AP-HP Hôpital Bicêtre (Le Kremlin-Bicêtre), Immunologie des Maladies Virales et Autoimmunes (IMVA - U1184), Université Paris-Sud - Paris 11 (UP11)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Institut National de la Santé et de la Recherche Médicale (INSERM), Médicaments et Technologies pour la Santé (MTS), Université Paris-Saclay-Direction de Recherche Fondamentale (CEA) (DRF (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Centre National de Référence de la Résistance aux Antibiotiques [CHU Rennes] (CNR), CHU Pontchaillou [Rennes], ARN régulateurs bactériens et médecine (BRM), Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES), NG Biotech, French National Reference Center for Antibiotic Resistance: Carbapenemase producing Enterobacteriaceae [Le Kremlin-Bicêtre], Assistance Publique-Hôpitaux de Paris (AP-HP), University Paris-Saclay, EIT health for the AMR-Detectool project, ANR-10-LABX-0033,LERMIT,Research Laboratory on Drugs and Therapeutic Innovation(2010), Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Serva, Camille, and Research Laboratory on Drugs and Therapeutic Innovation - - LERMIT2010 - ANR-10-LABX-0033 - LABX - VALID
- Subjects
Microbiology (medical) ,food.ingredient ,Bacterial growth ,Microbiology ,Agar plate ,03 medical and health sciences ,0302 clinical medicine ,food ,Bacterial Proteins ,Vancomycin ,[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases ,medicine ,Humans ,Agar ,Pharmacology (medical) ,030212 general & internal medicine ,Carbon-Oxygen Ligases ,[SDV.MP] Life Sciences [q-bio]/Microbiology and Parasitology ,Gram-Positive Bacterial Infections ,Immunoassay ,Pharmacology ,0303 health sciences ,medicine.diagnostic_test ,biology ,030306 microbiology ,Vancomycin Resistance ,biochemical phenomena, metabolism, and nutrition ,biology.organism_classification ,bacterial infections and mycoses ,3. Good health ,carbohydrates (lipids) ,Infectious Diseases ,[SDV.MP]Life Sciences [q-bio]/Microbiology and Parasitology ,Enterococcus ,[SDV.SP.PHARMA] Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology ,[SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseases ,[SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology ,bacteria ,Bacteria ,medicine.drug ,Lateral flow immunoassay - Abstract
Background VRE are nosocomial pathogens with an increasing incidence in recent decades. Rapid detection is crucial to reduce their spread and prevent infections and outbreaks. Objectives To evaluate a lateral flow immunoassay (LFIA) (called NG-Test VanA) for the rapid and reliable detection of VanA-producing VRE (VanA-VRE) from colonies and broth. Methods NG-Test VanA was validated on 135 well-characterized enterococcal isolates grown on Mueller–Hinton (MH) agar (including 40 VanA-VRE). Different agar plates and culture broths widely used in routine laboratories for culture of enterococci were tested. Results All 40 VanA-VRE clinical isolates were correctly detected in less than 15 min irrespective of the species expressing the VanA ligase and the medium used for bacterial growth. No cross-reaction was observed with any other clinically relevant ligases (VanB, C1, C2, D, E, G, L, M and N). Overall, the sensitivity and specificity of the assay were 100% for VanA-VRE grown on MH agar plates. NG-Test VanA accurately detects VanA-VRE irrespective of the culture medium (agar and broth). Band intensity was increased when using bacteria grown on vancomycin-containing culture media or on MH close to the vancomycin disc as a consequence of VanA induction. The limit of detection of the assay was 6.3 × 106 cfu per test with bacteria grown on MH plates and 4.9 × 105 cfu per test with bacteria grown on ChromID® VRE plates. Conclusions NG-Test VanA is efficient, rapid and easy to implement in the routine workflow of a clinical microbiology laboratory for the confirmation of VanA-VRE.
- Published
- 2021
25. Design and Analysis of Experiments: A Challenge Approach in Teaching
- Author
-
Pavao, Adrien, Kalainathan, Diviyan, Sun-Hosoya, Lisheng, Bennett, Kristen, Guyon, Isabelle, Laboratoire de Recherche en Informatique (LRI), Université Paris-Sud - Paris 11 (UP11)-CentraleSupélec-Centre National de la Recherche Scientifique (CNRS), TAckling the Underspecified (TAU), Université Paris-Sud - Paris 11 (UP11)-CentraleSupélec-Centre National de la Recherche Scientifique (CNRS)-Université Paris-Sud - Paris 11 (UP11)-CentraleSupélec-Centre National de la Recherche Scientifique (CNRS)-Inria Saclay - Ile de France, Institut National de Recherche en Informatique et en Automatique (Inria)-Institut National de Recherche en Informatique et en Automatique (Inria), Rensselaer Polytechnic Institute (RPI), Chalearn, and The project was funded in part by ChaLearn, Université Paris-Saclay 'big data' chair of Isabelle Guyon, the EU project HADACA (EIT Health) and the United Health Foundation (INCITE project, RPI, New York).
- Subjects
[STAT.ML]Statistics [stat]/Machine Learning [stat.ML] ,[MATH.MATH-ST]Mathematics [math]/Statistics [math.ST] ,ComputingMilieux_MISCELLANEOUS ,[INFO.INFO-AI]Computer Science [cs]/Artificial Intelligence [cs.AI] - Abstract
International audience
- Published
- 2019
26. Forkcipher: A New Primitive for Authenticated Encryption of Very Short Messages
- Author
-
Reza Reyhanitabar, Antoon Purnal, Elena Andreeva, Arnab Roy, Virginie Lallemand, Damian Vizár, IMEC (IMEC), Catholic University of Leuven - Katholieke Universiteit Leuven (KU Leuven), Cryptology, arithmetic : algebraic methods for better algorithms (CARAMBA), Department of Algorithms, Computation, Image and Geometry (LORIA - ALGO), Laboratoire Lorrain de Recherche en Informatique et ses Applications (LORIA), Centre National de la Recherche Scientifique (CNRS)-Université de Lorraine (UL)-Institut National de Recherche en Informatique et en Automatique (Inria)-Centre National de la Recherche Scientifique (CNRS)-Université de Lorraine (UL)-Institut National de Recherche en Informatique et en Automatique (Inria)-Laboratoire Lorrain de Recherche en Informatique et ses Applications (LORIA), Centre National de la Recherche Scientifique (CNRS)-Université de Lorraine (UL)-Institut National de Recherche en Informatique et en Automatique (Inria)-Centre National de la Recherche Scientifique (CNRS)-Université de Lorraine (UL)-Institut National de Recherche en Informatique et en Automatique (Inria)-Inria Nancy - Grand Est, Institut National de Recherche en Informatique et en Automatique (Inria), TE Connectivity Ltd, University of Bristol [Bristol], Centre Suisse d'Electronique et de Microtechnique SA [Neuchatel] (CSEM), Centre Suisse d'Electronique et Microtechnique SA (CSEM), Elena Andreeva was supported in part by the Research Council KU Leuven C1 on Security and Privacy for Cyber-Physical Systems and the Internet of Things with contract number C16/15/058 and by the Research Council KU Leuven, C16/18/004, through the EIT Health RAMSES project, through the IF/C1 on New Block Cipher Structures, and through the NIST project. In addition, this work was supported by the European Commission through the Horizon 2020 research and innovation programme under grant agreement H2020-DS-2014-653497 PANORAMIX and through the grant H2020-DS-SC7-2016-740507 Eunity. The work is supported in part by funding from imec of the Flemish Government. Antoon Purnal is supported by the Horizon 2020 research and innovation programme under Cathedral ERC Advanced Grant 695305. Reza Reyhanitabar’s work on this project was initiated when he was with KU Leuven and supported by an EU H2020-MSCA-IF fellowship under grant ID 708815, continued and submitted when he was with Elektrobit Automotive GmbH, and revised while he is now with TE Connectivity. Arnab Roy is supported by the EPSRC grant No. EPSRC EP/N011635/1., European Project: 708815,H2020,H2020-MSCA-IF-2015,POMEGRANATE(2017), European Project: 695305,Cathedral(2016), European Project: 653497,H2020,H2020-DS-2014-1,PANORAMIX(2015), European Project: 740507,EUNITY(2017), Inria Nancy - Grand Est, Institut National de Recherche en Informatique et en Automatique (Inria)-Institut National de Recherche en Informatique et en Automatique (Inria)-Department of Algorithms, Computation, Image and Geometry (LORIA - ALGO), Institut National de Recherche en Informatique et en Automatique (Inria)-Université de Lorraine (UL)-Centre National de la Recherche Scientifique (CNRS)-Institut National de Recherche en Informatique et en Automatique (Inria)-Université de Lorraine (UL)-Centre National de la Recherche Scientifique (CNRS)-Laboratoire Lorrain de Recherche en Informatique et ses Applications (LORIA), Institut National de Recherche en Informatique et en Automatique (Inria)-Université de Lorraine (UL)-Centre National de la Recherche Scientifique (CNRS)-Université de Lorraine (UL)-Centre National de la Recherche Scientifique (CNRS), Galbraith, SD, and Moriai, S
- Subjects
Authenticated encryption ,Computer science ,Short messages ,0102 computer and information sciences ,02 engineering and technology ,Encryption ,01 natural sciences ,law.invention ,[INFO.INFO-CR]Computer Science [cs]/Cryptography and Security [cs.CR] ,law ,0202 electrical engineering, electronic engineering, information engineering ,Lightweight cryptography ,Chosen-ciphertext attack ,Block cipher ,Forkcipher ,Authentication ,business.industry ,ForkSkinny ,Symmetric-key algorithm ,010201 computation theory & mathematics ,020201 artificial intelligence & image processing ,business ,Cryptanalysis ,Computer network ,Cryptographic nonce ,New primitive - Abstract
Highly efficient encryption and authentication of short messages is an essential requirement for enabling security in constrained scenarios such as the CAN FD in automotive systems (max. message size 64 bytes), massive IoT, critical communication domains of 5G, and Narrowband IoT, to mention a few. In addition, one of the NIST lightweight cryptography project requirements is that AEAD schemes shall be “optimized to be efficient for short messages (e.g., as short as 8 bytes)”. In this work we introduce and formalize a novel primitive in symmetric cryptography called forkcipher. A forkcipher is a keyed primitive expanding a fixed-lenght input to a fixed-length output. We define its security as indistinguishability under a chosen ciphertext attack (for n-bit inputs to 2n-bit outputs). We give a generic construction validation via the new iterate-fork-iterate design paradigm. We then propose 𝖥𝗈𝗋𝗄𝖲𝗄𝗂𝗇𝗇𝗒 as a concrete forkcipher instance with a public tweak and based on SKINNY: a tweakable lightweight cipher following the TWEAKEY framework. We conduct extensive cryptanalysis of 𝖥𝗈𝗋𝗄𝖲𝗄𝗂𝗇𝗇𝗒 against classical and structure-specific attacks. We demonstrate the applicability of forkciphers by designing three new provably-secure nonce-based AEAD modes which offer performance and security tradeoffs and are optimized for efficiency of very short messages. Considering a reference block size of 16 bytes, and ignoring possible hardware optimizations, our new AEAD schemes beat the best SKINNY-based AEAD modes. More generally, we show forkciphers are suited for lightweight applications dealing with predominantly short messages, while at the same time allowing handling arbitrary messages sizes. Furthermore, our hardware implementation results show that when we exploit the inherent parallelism of 𝖥𝗈𝗋𝗄𝖲𝗄𝗂𝗇𝗇𝗒 we achieve the best performance when directly compared with the most efficient mode instantiated with SKINNY. ispartof: pages:153-182 ispartof: International Conference on the Theory and Application of Cryptology and Information Security vol:11922 pages:153-182 ispartof: ASIACRYPT 2019 location:Kobe, Japan date:8 Dec - 12 Dec 2019 status: published
- Published
- 2019
27. Next-generation ARIA care pathways for rhinitis and asthma: A model for multimorbid chronic diseases
- Author
-
Bousquet, J.J. and Schünemann, H.J. and Togias, A. and Erhola, M. and Hellings, P.W. and Zuberbier, T. and Agache, I. and Ansotegui, I.J. and Anto, J.M. and Bachert, C. and Becker, S. and Bedolla-Barajas, M. and Bewick, M. and Bosnic-Anticevich, S. and Bosse, I. and Boulet, L.P. and Bourrez, J.M. and Brusselle, G. and Chavannes, N. and Costa, E. and Cruz, A.A. and Czarlewski, W. and Fokkens, W.J. and Fonseca, J.A. and Gaga, M. and Haahtela, T. and Illario, M. and Klimek, L. and Kuna, P. and Kvedariene, V. and Le, L.T.T. and Larenas-Linnemann, D. and Laune, D. and Lourenço, O.M. and Menditto, E. and Mullol, J. and Okamoto, Y. and Papadopoulos, N. and Pham-Thi, N. and Picard, R. and Pinnock, H. and Roche, N. and Roller-Wirnsberger, R.E. and Rolland, C. and Samolinski, B. and Sheikh, A. and Toppila-Salmi, S. and Tsiligianni, I. and Valiulis, A. and Valovirta, E. and Vasankari, T. and Ventura, M.-T. and Walker, S. and Williams, S. and Akdis, C.A. and Annesi-Maesano, I. and Arnavielhe, S. and Basagana, X. and Bateman, E. and Bedbrook, A. and Bennoor, K.S. and Benveniste, S. and Bergmann, K.C. and Bialek, S. and Billo, N. and Bindslev-Jensen, C. and Bjermer, L. and Blain, H. and Bonini, M. and Bonniaud, P. and Bouchard, J. and Briedis, V. and Brightling, C.E. and Brozek, J. and Buhl, R. and Buonaiuto, R. and Canonica, G.W. and Cardona, V. and Carriazo, A.M. and Carr, W. and Cartier, C. and Casale, T. and Cecchi, L. and Cepeda Sarabia, A.M. and Chkhartishvili, E. and Chu, D.K. and Cingi, C. and Colgan, E. and De Sousa, J.C. and Courbis, A.L. and Custovic, A. and Cvetkosvki, B. and Damato, G. and Da Silva, J. and Dantas, C. and Dokic, D. and Dauvilliers, Y. and Dedeu, A. and De Feo, G. and Devillier, P. and Di Capua, S. and Dykewickz, M. and Dubakiene, R. and Ebisawa, M. and El-Gamal, Y. and Eller, E. and Emuzyte, R. and Farrell, J. and Fink-Wagner, A. and Fiocchi, A. and Fontaine, J.F. and Gemicioǧlu, B. and Schmid-Grendelmeir, P. and Gamkrelidze, A. and Garcia-Aymerich, J. and Gomez, M. and Diaz, S.G. and Gotua, M. and Guldemond, N.A. and Guzmán, M.-A. and Hajjam, J. and O'Hourihane, J.B. and Humbert, M. and Iaccarino, G. and Ierodiakonou, D. and Ivancevich, J.C. and Joos, G. and Jung, K.-S. and Jutel, M. and Kaidashev, I. and Kalayci, O. and Kardas, P. and Keil, T. and Khaitov, M. and Khaltaev, N. and Kleine-Tebbe, J. and Kowalski, M.L. and Kritikos, V. and Kull, I. and Leonardini, L. and Lieberman, P. and Lipworth, B. and Lodrup Carlsen, K.C. and Loureiro, C.C. and Louis, R. and Mair, A. and Marien, G. and Mahboub, B. and Malva, J. and Manning, P. and De Manuel Keenoy, E. and Marshall, G.D. and Masjedi, M.R. and Maspero, J.F. and Mathieu-Dupas, E. and Matricardi, P.M. and Melén, E. and Melo-Gomes, E. and Meltzer, E.O. and Mercier, J. and Miculinic, N. and Mihaltan, F. and Milenkovic, B. and Moda, G. and Mogica-Martinez, M.-D. and Mohammad, Y. and Montefort, S. and Monti, R. and Morais-Almeida, M. and Mösges, R. and Münter, L. and Muraro, A. and Murray, R. and Naclerio, R. and Napoli, L. and Namazova-Baranova, L. and Neffen, H. and Nekam, K. and Neou, A. and Novellino, E. and Nyembue, D. and O'Hehir, R. and Ohta, K. and Okubo, K. and Onorato, G. and Ouedraogo, S. and Pali-Schöll, I. and Palkonen, S. and Panzner, P. and Park, H.-S. and Pépin, J.-L. and Pereira, A.-M. and Pfaar, O. and Paulino, E. and Phillips, J. and Plavec, D. and Popov, T.A. and Portejoie, F. and Price, D. and Prokopakis, E.P. and Pugin, B. and Raciborski, F. and Rajabian-Söderlund, R. and Reitsma, S. and Rodo, X. and Romano, A. and Rosario, N. and Rottem, M. and Ryan, D. and Salimäki, J. and Sanchez-Borges, M.M. and Sisul, J.-C. and Solé, D. and Somekh, D. and Sooronbaev, T. and Sova, M. and Spranger, O. and Stellato, C. and Stelmach, R. and Ulrik, C.S. and Thibaudon, M. and To, T. and Todo-Bom, A. and Tomazic, P.V. and Valero, A.A. and Valenta, R. and Valentin-Rostan, M. and Van Der Kleij, R. and Vandenplas, O. and Vezzani, G. and Viart, F. and Viegi, G. and Wallace, D. and Wagenmann, M. and Wang, D.Y. and Waserman, S. and Wickman, M. and Williams, D.M. and Wong, G. and Wroczynski, P. and Yiallouros, P.K. and Yorgancioglu, A. and Yusuf, O.M. and Zar, H.J. and Zeng, S. and Zernotti, M. and Zhang, L. and Zhong, N.S. and Zidarn, M., MACVIA-France, Fondation Partenariale FMC VIA-LR, CHU, Montpellier Cedex 5, 34295, France, INSERM U 1168, VIMA: Ageing and Chronic Diseases Epidemiological and Public Health Approaches, Villejuif Université Versailles St-Quentin-en-Yvelines, UMR-S 1168, Montigny Le Bretonneux, France, European Forum for Research and Education in Allergy and Airway Diseases (EUFOREA), Brussels, Belgium, Humboldt-Uniersität zu Berlin, Berlin, Germany, Department of Dermatology and Allergy, Comprehensive Allergy-Centre, Berlin Institute of Health, Berlin, Germany, Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, ON, Canada, Division of Allergy, Immunology, and Transplantation (DAIT), National Institute of Allergy and Infectious Diseases, NIH, Bethesda, United States, National Institute for Health and Welfare, Helsinki, Finland, Dept. of Otorhinolaryngology, Univ Hospitals Leuven, Louvain, Belgium, Academic Medical Center, Univ of Amsterdam, Amsterdam, Netherlands, Faculty of Medicine, Transylvania University, Brasov, Romania, Department of Allergy and Immunology, Hospital Quirónsalud Bizkaia, Erandio, Spain, ISGlobAL, Centre for Research in Environmental Epidemiology (CREAL), Barcelona, Spain, IMIM (Hospital del Mar Research Institute), Barcelona, Spain, CIBER Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain, Universitat Pompeu Fabra (UPF), Barcelona, Spain, Upper Airways Research Laboratory, ENT Dept., Ghent University Hospital, Ghent, Belgium, Dept. of Otolaryngology, Head and Neck Surgery, University of Mainz, Mainz, Germany, Hospital Civil de Guadalajara Dr Juan I Menchaca, Guadalarara, Mexico, iQ4U Consultants Ltd., London, United Kingdom, Woolcock Institute of Medical Research, University of Sydney, Sydney, Australia, Woolcock Emphysema Centre, Sydney, Australia, Sydney Local Health District, Glebe, NSW, Australia, La Rochelle, France, Quebec Heart and Lung Institute, Laval University, Quebec City, QC, Canada, EIT Health France, Paris, France, Dept. of Respiratory Medicine, Ghent University Hospital, Ghent, Belgium, Department of Public Health and Primary Care, Leiden University Medical Center, Leiden, Netherlands, UCIBIO, REQUINTE, Faculty of Pharmacy, Competence Center on Active and Healthy Ageing, University of Porto (Porto4Ageing), Porto, Portugal, ProAR-Nucleo de Excelencia em Asma, Federal University of Bahia, Bahia, Brazil, WHO GARD Planning Group, Salvador, Brazil, Medical Consulting Czarlewski, Levallois, France, Department of Otorhino-Laryngology, Amsterdam University Medical Centres, AMC, Amsterdam, Netherlands, CINTESIS, Center for Research in Health Technology and Information Systems, Faculdade de Medicina da Universidade do Porto, Porto, Portugal, Medida, Lda Porto, Portugal, Athens Chest Hospital, 7th Resp. Med. Dept. and Asthma Center, Athens, Greece, Skin and Allergy Hospital, Helsinki University Hospital, University of Helsinki, Helsinki, Finland, Division for Health Innovation, Campania Region and Federico II University Hospital Naples (R and D and DISMET), Naples, Italy, Center for Rhinology and Allergology, Wiesbaden, Germany, Division of Internal Medicine, Asthma and Allergy, Barlicki University Hospital, Medical University of Lodz, Łódź, Poland, Faculty of Medicine, Vilnius University, Vilnius, Lithuania, University of Medicine and Pharmacy, Hochiminh City, Viet Nam, Center of Excellence in Asthma and Allergy, Médica Sur Clinical Foundation and Hospital, México City, Mexico, KYomed INNOV, Montpellier, France, Faculty of Health Sciences and CICS-UBI, Health Sciences Research Centre, University of Beira Interior, Covilhã, Portugal, CIRFF, Federico II University, Naples, Italy, Rhinology Unit and Smell Clinic, ENT Department, Hospital Clínic, Barcelona, Spain, Clinical and Experimental Respiratory Immunoallergy, IDIBAPS, CIBERES, University of Barcelona, Barcelona, Spain, Dept. of Otorhinolaryngology, Chiba University Hospital, Chiba, Japan, Division of Infection, Immunity and Respiratory Medicine, Royal Manchester Children's Hospital, University of Manchester, Manchester, United Kingdom, Allergy Department, 2nd Pediatric Clinic, Athens General Children's Hospital P and A Kyriakou, University of Athens, Athens, Greece, Allergy Department, Pasteur Institute, Paris, France, Conseil General de l'Economie Ministere de l'Economie, de l'Industrie et du Numerique, Paris, France, Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, United Kingdom, Pneumologie et Soins Intensifs Respiratoires, Hôpitaux Universitaires Paris, Centre Hôpital Cochin, Paris, France, Department of Internal Medicine, Medical University of Graz, Graz, Austria, Association Asthme et Allergie, Paris, France, Department of Prevention of Environmental Hazards and Allergology, Medical University of Warsaw, Warsaw, Poland, Health Planning Unit, Department of Social Medicine, Faculty of Medicine, University of Crete, Crete, Greece, International Primary Care Respiratory Group IPCRG, Aberdeen, United Kingdom, Institute of Clinical Medicine, Institute of Health Sciences, Vilnius University, Faculty of Medicine, Vilnius, Lithuania, Department of Lung Diseases and Clinical Immunology, University of Turku and Terveystalo Allergy Clinic, Turku, Finland, FILHA, Finnish Lung Association, Helsinki, Finland, Unit of Geriatric Immunoallergol-ogy, University of Bari Medical School, Bari, Italy, Asthma UK, Mansell Street, London, United Kingdom, Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland, Epidemiology of Allergic and Respiratory Diseases, Department Institute Pierre Louis of Epidemiology and Public Health, INSERM and Sorbonne Université, Medical School Saint Antoine, Paris, France, Department of Medicine, University of Cape Town, Cape Town, South Africa, Dept. of Respiratory Medicine, National Institute of Diseases of the Chest and Hospital, Dhaka, Bangladesh, National Center of Expertise in Cognitive Stimulation (CEN STIMCO), Broca Hospital, Paris, France, Department of Biochemistry and Clinical Chemistry, Faculty of Pharmacy, Division of Laboratory Medicine, Warsaw Medical University, Warsaw, Poland, Global Alliance Against Chronic Respiratory Diseases (WHO GARD), Joensuu, Finland, Department of Dermatology and Allergy Centre, Odense University Hospital, Odense Research Center for Anaphylaxis (ORCA), Odense, Denmark, Termofscher Scientific, Uppsala, Sweden, Department of Respiratory Medicine and Allergology, University Hospital, Lund, Sweden, Department of Geriatrics, Montpellier University hospital, Montpellier, France, EA 2991 Euromov, University Montpellier, Montpellier, France, UOC Pneumologia, Istituto di Medicina Interna, F Policlinico Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy, National Heart and Lung Institute, Royal Brompton Hospital, Imperial College, London, United Kingdom, CHU, Dijon, France, Clinical Medicine, Laval's University, Quebec City, Canada, Medicine Department, Hôpital de la Malbaie, Quebec city, QC, Canada, Department of Clinical Pharmacy of Lithuanian, University of Health, Kaunas, Lithuania, Institute of Lung Health, Respiratory Biomedical Unit, University Hospitals of Leicester NHS Trust, Leicestershire, United Kingdom, Department of Infection, Immunity and Inflammation, University of Leicester, Leicester, United Kingdom, Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Mainz, Germany, Municipality Pharmacy, Sarno, Italy, Personalized Medicine Clinic Asthma and Allergy, Humanitas University, Humanitas Research Hospital, Rozzano, Milan, Italy, Allergy Section, Department of Internal Medicine, Hospital Vall d'Hebron, ARADyAL Research Network, Barcelona, Spain, Regional Ministry of Health of Andalu-sia, Seville, Spain, Allergy and Asthma Associates of Southern California, Mission Viejo, CA, United States, ASA-Advanced Solutions Accelerator, Clapiers, France, Division of Allergy/Immunology, University of South Florida, Tampa, FL, United States, SOS Allergology and Clinical Immunology, USL Toscana Centro, Prato, Italy, Allergy and Immunology Laboratory, Metropolitan University, Simon Bolivar University, Barranquilla, Colombia, SLaai, Sociedad Lati-noamericana de Allergia, Asma e Immunologia, Barranquilla, Colombia, Chachava Clinic, David Tvildiani Medical University-AIETI Medical School, Grigol Robakidze University, Tbilisi, Georgia, Medical Faculty, ENT Department, Eskisehir Osmangazi University, Eskisehir, Turkey, Department of Health, Social Services and Public Safety, Belfast, Northern Ireland, United Kingdom, Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Braga, Portugal, PT Government Associate Laboratory, ICVS/3B's, Braga/Guimarães, Portugal, Ecole des Mines, Alès, France, Centre for Respiratory Medicine and Allergy, Institute of Inflammation and Repair, University of Manchester, University Hospital of South Manchester, Manchester, United Kingdom, Division of Respiratory and Allergic Diseases, Department of Respiratory Diseases, High Specialty Hospital A. Cardarelli, Naples, Italy, Allergy Service, University Hospital of Federal University of Santa Catarina (HU-UFSC), Florianópolis, Brazil, Cáritas Diocesana de Coimbra, Coimbra, Portugal, Ageing at Coimbra EIP-AHA Reference Site, Coimbra, Portugal, Medical Faculty Skopje, University Clinic of Pulmonology and Allergy, Skopje, North Macedonia, Sleep Unit, Department of Neurology, Hôpital Gui-de-Chauliac Montpellier, Inserm U1061, Montpellier, France, AQuAS, Barcelna, Spain, EUREGHA, European Regional and Local Health Association, Brussels, Belgium, Department of Medicine, Surgery and Dentistry Scuola Medica Salernitana, University of Salerno, Salerno, Italy, UPRES EA220, Pôle des Maladies des Voies Respiratoires, Hôpital Foch, Université Paris-Saclay, Suresnes, France, Farmacie Dei Golfi Group, Massa Lubrense, Italy, Section of Allergy and Immunology, Saint Louis University School of Medicine, Saint Louis, MO, United States, Clinic of Infectious, Chest Diseases, Dermatology and Allergology, Vilnius University, Vilnius, Lithuania, Clinical Reserch Center for Allergy and Rheumatology, Sagamihara National Hospital, Sagamihara, Japan, Pediatric Allergy and Immunology Unit, Children's Hospital, Ain Shams University, Cairo, Egypt, Clinic of Children's Diseases, Faculty of Medicine, Vilnius University, Vilnius, Lithuania, Global Allergy and Asthma Platform GAAPP, Vienna, Austria, Division of Allergy, Department of Pediatric Medicine, Bambino Gesù Children's Research Hospital Holy See, Rome, Italy, Reims, France, Department of Pulmonary Diseases, Istanbul University-Cerrahpasa, Cerrahpasa Faculty of Medicine, Istambul, Turkey, Allergy Unit, Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland, National Center for Disease Control and Public Health of Georgia, Tbilisi, Georgia, Allergy and Asthma Unit, Hospital San Bernardo Salta, Salta, Argentina, Universidad Autónoma de Nuevo León, San Nicolás de los Garza, Mexico, Center of Allergy and Immunology, Georgian Association of Allergology and Clinical Immunology, Tbilisi, Georgia, Institute of Health Policy and Management iBMG, Erasmus University, Rotterdam, Netherlands, Immunology and Allergy Division, Clinical Hospital, University of Chile, Santiago, Chile, Centich: Centre d'Expertise National des Technologies de l'Information et de la Communication pour l'Autonomie, Gérontopôle Autonomie Longévité des Pays de la Loire, Conseil Régional des Pays de la Loire, Centre d'Expertise Partenariat Europeen d'Innovation pour un Vieillissement Actif et en Bonne Sante, Nantes, France, Department of Paediatrics and Child Health, University College Cork, Cork, Ireland, Université Paris-Sud, Service de Pneumologie, Hôpital Bicêtre, Inserm UMR-S999, Le Kremlin Bicêtre, France, Department of Medicine and Surgery, University of Salerno, Baronissi, Italy, Servicio de Alergia e Immunologia, Clinica Santa Isabel, Buenos Aires, Argentina, Hallym University College of Medicine, Hallym University Sacred Heart Hospital, Anyang, Gyeonggi-do, South Korea, Department of Clinical Immunology, Wrocław Medical University, Wrocław, Poland, Ukrainian Medical Stomatological Academy, Poltava, Ukraine, Pediatric Allergy and Asthma Unit, Hacettepe University School of Medicine, Ankara, Turkey, First Department of Family Medicine, Medical University of Lodz, Łódź, Poland, Institute of Social Medicine, Epidemiology and Health Economics, Charité-Universitätsmedizin Berlin, Berlin, Germany, Institute for Clinical Epidemiology and Biometry, University of Wuerzburg, Würzburg, Germany, National Research Center, Institute of Immunology, Federal Medicobiological Agency, Laboratory of Molecular Immunology, Moscow, Russian Federation, GARD, Geneva, Switzerland, Allergy and Asthma Center Westend, Berlin, Germany, Department of Immunology and Allergy, Healthy Ageing Research Center, Medical University of Lodz, Łódź, Poland, Department of Clinical Science and Education, Södersjukhuset, Karolinska Institutet, Stockholm, Sweden, Sach's Children and Youth Hospital, Södersjukhuset, Stockholm, Sweden, Mattone Internazionale Program, Veneto Region, Italy, Departments of Internal Medicine and Pediatrics (Divisions of Allergy and Immunology), University of Tennessee College of Medicine, Germantown, TN, United States, Scottish Centre for Respiratory Research, Cardiovascular and Diabetes Medicine, Medical Research Institute, Ninewells Hospital, University of Dundee, Dundee, United Kingdom, Department of Paediatrics, Oslo University Hospital, Oslo, Norway, Faculty of Medicine, Institute of Clinical Medicine, University of Oslo, Oslo, Norway, Imunoalergologia, Centro Hospitalar Universitário de Coimbra, Faculty of Medicine, University of Coimbra, Coimbra, Portugal, Department of Pulmonary Medicine, CHU Sart-Tilman, GIGA I3 Research Group, Liege, Belgium, DG for Health and Social Care, Scottish Government, Edinburgh, United Kingdom, Department of Pulmonary Medicine, Rashid Hospital, Dubai, United Arab Emirates, Coimbra Institute for Clinical and Biomedical Research (iCBR), Faculty of Medicine, University of Coimbra, Coimbra, Portugal, Department of Medicine (RCSI), Bon Secours Hospital, Glasnevin, Dublin, Ireland, Kronikgune, International Centre of Excellence in Chronicity Research Barakaldo, Barakaldo, Bizkaia, Spain, Division of Clinical Immunology and Allergy, Laboratory of Behavioral Immunology Research, University of Mississippi Medical Center, Jackson, MS, United States, Tobacco Control Research Centre, Iranian Anti Tobacco Association, Tehran, Iran, Argentine Association of Allergy and Clinical Immunology, Buenos Aires, Argentina, Department of Pediatric Pneumology and Immunology, AG Molecular Allergology and Immunomodulation, Charité Medical University, Berlin, Germany, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, PNDR, Portuguese National Programme for Respiratory Diseases, Faculdade de Medicina de Lisboa, Lisbon, Portugal, Allergy and Asthma Medical Group and Research Center, San Diego, CA, United States, Department of Physiology, CHRU, University Montpellier, PhyMedExp, INSERM U1046, CNRS, UMR 9214, Montpellier, France, Croatian Pulmonary Society, Zagreb, Croatia, National Institute of Pneumology M Nasta, Bucharest, Romania, Clinic for Pulmonary Diseases, Clinical Center of Serbia, Faculty of Medicine, University of Belgrade, Serbian Association for Asthma and COPD, Belgrade, Serbia, Regione Piemonte, Turin, Italy, Mexico City, Mexico, National Center for Research in Chronic Respiratory Diseases, Tishreen University School of Medicine, Latakia, Syrian Arab Republic, Syrian Private University, Damascus, Syrian Arab Republic, Faculty of Medicine and Surgery, University of Medicine, La Valette, Malta, Department of Medical Sciences, Allergy and Clinical Immunology Unit, University of Torino, Mauriziano Hospital, Turin, Italy, Allergy Center, CUF Descobertas Hospital, Lisbon, Portugal, Institute of Medical Statistics, and Computational Biology, Medical Faculty, University of Cologne, Cologne, Germany, CRI-Clinical Research International-Ltd, Hamburg, Germany, Danish Commitee for Health Education, Copenhagen East, Denmark, Food Allergy Referral Centre Veneto Region, Department of Women and Child Health, Padua General University Hospital, Padua, Italy, MedScript Ltd., Paraparomu, New Zealand, OPC, Cambridge, United Kingdom, Johns Hopkins School of Medicine, Baltimore, MD, United States, Consortium of Pharmacies and Services COSAFER, Salerno, Italy, Scientific Centre of Children's Health under the Russian Academy of Medical Sciences, Moscow, Russian Federation, Center of Allergy, Immunology and Respiratory Diseases, Santa Fe, Argentina, Center for Allergy and Immunology, Santa Fe, Argentina, Hospital of the Hospitaller Brothers in Buda, Budapest, Hungary, Die Hautambulanz and Rothhaar Study Center, Berlin, Germany, Department of Pharmacy, University of Naples Federico II, Naples, Italy, ENT Department, University Hospital of Kinshasa, Kinshasa, Democratic Republic Congo, Department of Allergy, Immunology and Respiratory Medicine, Alfred Hospital and Central Clinical School, Monash University, Melbourne, VIC, Australia, Dept. of Otolaryngology, Nippon Medical School, Tokyo, Japan, Centre Hospitalier Universitaire Pédiatrique Charles de Gaulle, Ouagadougou, Burkina Faso, Dept. of Comparative Medicine, Messerli Research Institute, University of Veterinary Medicine and Medical University, Vienna, Austria, EFA European Federation of Allergy and Airways Diseases Patients' Associations, Brussels, Belgium, Department of Immunology and Allergology, Faculty of Medicine and Faculty Hospital in Pilsen, Charles University in Prague, Pilsen, Czech Republic, Department of Allergy and Clinical Immunology, Ajou University School of Medicine, Suwon, South Korea, Laboratoire HP2, Université Grenoble Alpes, Grenoble, France, INSERM, U1042, CHU de Grenoble, Grenoble, France, Allergy Unit, CUF-Porto Hospital and Institute, Porto, Portugal, Center for Research in Health Technologies and Information Systems, CINTESIS, Universidade do Porto, Porto, Portugal, Maladies Infectieuses et immunitaires, CHUL, Quebec City, QC, Canada, Department of Otorhinolaryngology, Head and Neck Surgery, Section of Rhinology and Allergy, University Hospital Marburg, Philipps-Universität Marburg, Marburg, Germany, Farmacias Holon, Lisbon, Portugal, Centre for Empowering Patients and Communities, Faulkland, Somerset, United Kingdom, Children's Hospital Srebrnjak, Zagreb, Croatia, School of Medicine, University J.J. Strossmayer, Osijek, Croatia, University Hospital 'Sv Ivan Rilski', Sofia, Bulgaria, Academic Centre of Primary Care, University of Aberdeen, Aberdeen, United Kingdom, Research in Real-Life, Cambridge, United Kingdom, Department of Otorhinolaryngology, University of Crete School of Medicine, Heraklion, Greece, Department of Nephrology and Endocrinology, Karolinska University Hospital, Stockholm, Sweden, Allergy Unit, Presidio Columbus, Catholic University of Sacred Heart, Rome, Italy, IRCCS Oasi Maria SS, Troina, Italy, Hospital de Clinicas, University of Parana, Paraná, Brazil, Division of Allergy Asthma and Clinical Immunology, Emek Medical Center, Afula, Israel, Allergy and Respiratory Research Group, University of Edinburgh, Edinburgh, United Kingdom, Association of Finnish Pharmacists, Helsinki, Finland, Allergy and Clinical Immunology Department, Centro Médico-Docente la, Trinidad and Clínica El Avila, Caracas, Venezuela, Sociedad Paraguaya de Alergia Asma e Inmunologia, Asunción, Paraguay, Division of Allergy, Clinical Immunology and Rheumatology, Department of Pediatrics, Federal University of São Paulo, São Paulo, Brazil, European Health Futures Forum (EHFF), Dromahair, United Kingdom, Kyrgyzstan National Centre of Cardiology and Internal Medicine, Euro-Asian Respiratory Society, Bishkek, Kyrgyzstan, Department of Respiratory Medicine, University Hospital Olomouc, Olomouc, Czech Republic, Pulmonary Division, Heart Institute (InCor), Hospital da Clinicas da Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, Brazil, Department of Respiratory Medicine, Hvidovre Hospital and University of Copenhagen, Copenhagen, Denmark, RNSA (Réseau National de Surveillance Aérobiologique), Brussieu, France, Sidkkids Hospitala and Institute of Health Policy, Management and Evaluation, Toronto, Canada, Department of ENT, Medical University of Graz, Graz, Austria, Pneumology and Allergy Department, CIBERES and Clinical and Experimental Respiratory Immunoallergy, IDIBAPS, University of Barcelona, Barcelona, Spain, Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria, NRC Institute of Immunology FMBA of Russia, Moscow, Russian Federation, Laboratory of Immunopathology, Department of Clinical Immunology and Allergy, Sechenov First Moscow State Medical University, Moscow, Russian Federation, Montevideo, Uruguay, Department of Public Health and Primary Care, Leiden University Medical Center (LUMC), Leiden, Netherlands, Department of Obstetrics and Gynaecology, Erasmus MC, University Medical Center, Rotterdam, Netherlands, Department of Chest Medicine, Centre Hospitalier Universitaire UCL Namur, Université Catholique de Louvain, Yvoir, Belgium, Pulmonary Unit, Department of Medical Specialties, Arcispedale SMaria Nuova/IRCCS, AUSL di Reggio Emilia, Reggio Emilia, Italy, Pulmonary Environmental Epidemiology Unit, CNR Institute of Clinical Physiology, Pisa, Italy, CNR Institute of Biomedicine and Molecular Immunology A Monroy, Palermo, Italy, Nova Southeastern University, Fort Lauderdale, FL, United States, Dept. of Otorhinolaryngology, HNO-Klinik, Universitätsklinikum Düsseldorf, Düsseldorf, Germany, Department of Otolaryngology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore, Department of Medicine, Clinical Immunology and Allergy, McMaster University, Hamilton, ON, Canada, Centre for Clinical Research Sörmland, Uppsala University, Eskilstuna, Sweden, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, United States, Cyprus International Institute for Environmental, Public Health in Association with Harvard School of Public Health, Cyprus University of Technology, Limassol, Cyprus, Department of Pediatrics, Hospital Archbishop Makarios III, Nicosia, Cyprus, Department of Pulmonary Diseases, Celal Bayar University, Faculty of Medicine, Manisa, Turkey, Allergy and Asthma Institute, Islamabad, Pakistan, Department of Paediatrics and Child Health, Red Cross Children's Hospital, Cape Town, South Africa, MRC Unit on Child and Adolescent Health, University of Cape Town, Cape Town, South Africa, Bull DSAS, Echirolles, France, Universidad Católica de Córdoba, Córdoba, Argentina, Department of Otolaryngology Head and Neck Surgery, Beijing TongRen Hospital, Beijing Institute of Otolaryngology, Beijing, China, State Key Laboratory of Respiratory Diseases, Guangzhou Institute of Respiratory Disease, First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China, University Clinic of Respiratory and Allergic Diseases, Golnik, Slovenia, and National Hospital Organization, Tokyo National Hospital, Tokyo, Japan
- Abstract
Background: In all societies, the burden and cost of allergic and chronic respiratory diseases are increasing rapidly. Most economies are struggling to deliver modern health care effectively. There is a need to support the transformation of the health care system into integrated care with organizational health literacy. Main body: As an example for chronic disease care, MASK (Mobile Airways Sentinel NetworK), a new project of the ARIA (Allergic Rhinitis and its Impact on Asthma) initiative, and POLLAR (Impact of Air POLLution on Asthma and Rhi-nitis, EIT Health), in collaboration with professional and patient organizations in the field of allergy and airway diseases, are proposing real-life ICPs centred around the patient with rhinitis, and using mHealth to monitor environmental exposure. Three aspects of care pathways are being developed: (i) Patient participation, health literacy and self-care through technology-assisted "patient activation", (ii) Implementation of care pathways by pharmacists and (iii) Next-generation guidelines assessing the recommendations of GRADE guidelines in rhinitis and asthma using real-world evidence (RWE) obtained through mobile technology. The EU and global political agendas are of great importance in supporting the digital transformation of health and care, and MASK has been recognized by DG Santé as a Good Practice in the field of digitally-enabled, integrated, person-centred care. Conclusion: In 20 years, ARIA has considerably evolved from the first multimorbidity guideline in respiratory diseases to the digital transformation of health and care with a strong political involvement. © The Author(s) 2019.
- Published
- 2019
28. Allergic Rhinitis and its Impact on Asthma (ARIA) Phase 4 (2018): Change management in allergic rhinitis and asthma multimorbidity using mobile technology
- Author
-
Karin C. Lødrup Carlsen, L. Cecchi, F. Portejoie, T. Vontetsianos, Olivier Vandenplas, M. van Hague, D. Mora Bogado, M. Illario, Dana Wallace, L. Namazova-Baranova, E. Asayag, I. Ribeirinho, E. Costa, Shona Pedersen, Inger Kull, Davor Plavec, M. Morais-Almeida, Mickael Bewick, N.H. Chavannes, I. J. Ansotegui, G. De Carlo, K. S. Bennoor, Faradiba Sarquis Serpa, S. Arnavielle, F. Corti, Moises A. Calderon, Martín Bedolla-Barajas, Mette Sørensen, Isabella Annesi-Maesano, Elaine Colgan, Przemyslaw Kardas, M. van Eerd, Jorge Maspero, Valérie Siroux, Isabelle Momas, Ralph Mösges, Yves Dauvilliers, T. Keil, T. Bieber, Marit Westman, Rachel Nadif, O. Pfaar, A.C. Carvalho Coehlo, R. M. Cortés-Grimaldo, I. Skrindo, Piotr Kuna, Nicola Scichilone, Antonella Muraro, Kimihiro Okubo, Paulo Augusto Moreira Camargos, C. Cartier, Oliver Pfaar, K. Ohta, Barbara P. Yawn, Igor Kaidashev, Michel Thibaudon, X. Basagana, I. Kaidashev, Bilun Gemicioglu, S. Genova, Hae-Sim Park, J.J. Matta Campos, Simon Walker, Ulf Darsow, Fulvio Braido, J. Salimäki, T. Zuberbier, Raphaël Chiron, Mohammad Reza Masjedi, G.D. Marshall, Branislava Milenkovic, W. J. Fokkens, Eric D. Bateman, Robert M. Naclerio, Steve Montefort, M. de Fátima Emerson, T. Werfel, Cemal Cingi, A. Szylling, Martin Wagenmann, I. Baiardini, L. T. T. Le, N. Khaltaev, Ki-Suck Jung, Agnieszka Lipiec, Panayiotis K. Yiallouros, A Valero, R. Gerth van Wijk, L. Hernández, Marek L. Kowalski, C. Zubrinich, Sinthia Bosnic-Anticevich, Miguel A. Sierra, Erik Melén, T. Haahtela, Rute Almeida, Violeta Kvedariene, R. Pawankar, T.A. Popov, Flore Amat, Sanna Toppila-Salmi, M. Gotua, A. Sheikh, A. Bedbrook, Torsten Zuberbier, B. De Martino, Gérard Dray, Francesca Avolio, E. Mandajieva, B. Samolinski, Petr Panzner, P. Kuna, Philippe-Jean Bousquet, T. D. Nyembue, Luo Zhang, Leyla Namazova-Baranova, Ana Maria Carriazo, João Fonseca, E. Van Ganse, Roland Buhl, M. Bochenska Marciniak, Cristiana Stellato, J. da Silva, J. E. Gereda, Han-Jung Park, M.C. Costa-Dominguez, W. Carr, Dirceu Solé, S. Forti, Nanshan Zhong, Jordi Sunyer, Alain Didier, Y. Z. Chen, Thomas B. Casale, Jim Phillips, Isabelle Bosse, Manuel Teixeira Veríssimo, D. Y. Wang, U. Trama, Cristina Bárbara, David Somekh, T. Camuzat, R. N. Naclerio, Enrico Novellino, Leszek Klimek, M. Rodriguez Gonzalez, Holger J. Schünemann, Mario Barbagallo, D. Larenas-Linnemann, Mario Sánchez-Borges, Massimo Triggiani, Y. Okamoto, E. Mathieu-Dupas, N. Di Carluccio, S. Toppila-Salmi, Omer Kalayci, Rudolf Valenta, J. Coll, F. de Blay, Wienczyslawa Czarlewski, W. Pohl, Piotr Wroczyński, Kian Fan Chung, Nikolaos G. Papadopoulos, Pascal Demoly, Hubert Blain, M. Crescenzo, O. Kalayci, Leocadio Rodríguez-Mañas, G. Moda, L. Cox, Z. Gutter, A. Mair, Andrew Bush, Maria-Dolores Mogica-Martinez, Giorgio Walter Canonica, Antonio Valero, Daniel Laune, A. Zurkuhlen, Paul C. Potter, D. Wallace, Gabrielle L. Onorato, Mihaela Zidarn, E.P. Prokopakis, Anne Lise Courbis, Sergio Bonini, Ruta Dubakiene, A. Papi, Y. El-Gamal, Jacques Mercier, Wytske Fokkens, Rodolphe Bourret, S. Palkonen, A. Yorgancioglu, G. Vezzani, J. A. Rizzo, D. Plavec, D. Caillot, G. De Feo, E. Menditto, Caterina Bucca, A. C. Pozzi, Hironori Sagara, I. Grisle, I. Pin, Christopher E. Brightling, Ludger Klimek, F.F. Morato-Castro, Désirée Larenas-Linnemann, Alessandro Vatrella, A. A. Cruz, Guy Joos, E.D. Bateman, Erendira Rodriguez-Zagal, H. Douagui, T. To, Edgardo Jares, C. Bindslev-Jensen, G. Levato, J. O. B. Hourihane, R. Rajabian-Soderlund, C. Odzhakova, J. Bousquet, M. T. Ventura, Arzu Yorgancioglu, Osman M. Yusuf, H. J. Zar, Giovanni Rolla, Sebastian L. Johnston, M.S. Dykewicz, Esben Eller, A. Gamkrelidze, Filip Raciborski, Renzo Angles, Rafael Stelmach, M. Nogues, David Price, Mário Morais-Almeida, Tari Haahtela, Teresa To, D. Conforti, Stephen R. Durham, S. Gonzalez Diaz, V. Cardona, Werner Aberer, B. Milenkovic, Luigi Napoli, K. C. Bergmann, P W Hellings, M. Lessa, P. Panzner, Alfonso M. Cepeda Sarabia, M. Guidacci, A.L. Matos, Todor A. Popov, C. Suppli Ulrik, Diana Deleanu, N. de Paula Motta Rubini, Carsten Bindslev-Jensen, I. Majer, Ioana Agache, B. A. Barreto, R. Picard, Erkka Valovirta, A. Fink-Wagner, L. Colas, João O. Malva, Thomas Keil, M. T. Burguete Cabañas, Bolesław Samoliński, M.H. Garcia-Cruz, L.P. Boulet, K. Nekam, Edyta Krzych-Fałta, P. Devillier, J. Ferreira de Mello, Jussi Karjalainen, I. Bogus-Buczynska, Susan Waserman, Marcus Maurer, Tomas Chivato, Elena Bacci, M. Przemecka, Olga Lourenço, José Miguel Fuentes-Pérez, M. Zidarn, Talant Sooronbaev, J.M. Anto, W. Czarlewski, R. Murray, Luís Nogueira-Silva, G. Passalacqua, E. Chkhartishvili, Oscar Mayora, Victoria Cardona, M. Sondermann, Piotr Lacwik, S. Ouedraogo, I. Baroni, Artur Z. Białoszewski, G Scadding, J. Strozek, R. Emuzyte, Neven Miculinic, Ruby Pawankar, Ken Ohta, I. Agache, J.L. Gálvez-Romero, Nikos G. Papadopoulos, E. O. Meltzer, I. Annesi-Maesano, E. De Manuel Keenoy, Jorge A. Luna-Pech, Ana Margarida Pereira, Paul Potter, M. Ortega Cisneros, J. Li, K. F. Rabe, M. Rottem, Mikael Benson, Ali Fuat Kalyoncu, Dermot Ryan, Dieter Maier, C.Y. García-Cobas, S. Bialek, G. Du Toit, S. Shamai, S. Mavale-Manuel, Rojin Rajabian-Soderlund, Maddalena Illario, Philippe Devillier, F. Rodenas, Emmanuel P. Prokopakis, De Yun Wang, Niels H. Chavannes, E.H.D. Bel, Bianca Beghe, Sietze Reitsma, John Wright, O. Lourenço, L.T.T. Le, Josep M. Antó, T. Casale, Paul K. Keith, K. C. Lødrup Carlsen, P. Demoly, Mikael Kuitunen, Marc Humbert, A. M. Cepeda Sarabia, Ignacio J. Ansotegui, M.C. Rizzo, Davide Caimmi, Milan Sova, Nick A. Guldemond, P. Yakovliev, Judah A. Denburg, Jaime Correia de Sousa, Elisabete Melo-Gomes, Aziz Sheikh, I. Bosse, M. M. Ciaravolo, S. Di Capua Ercolano, Alpana Mair, P. Lieberman, Isabella Pali-Schöll, Leif Bjermer, G. De Vries, M. Roman Rodriguez, Johanna Salimäki, Carmen Panaitescu, F. Mihaltan, Giulia De Feo, F. E. R. Simons, A. Blua, B. Mahboub, D. Ryan, M. Bewick, Anabela Mota-Pinto, J.A. Fonseca, Neil Wilson, Marek Jutel, Dennis M. Williams, M. Akdis, Menachem Rottem, Marcello Persico, J. C. Ivancevich, Nelson Rosario, A. Farsi, Alvaro A. Cruz, Liguo Zhang, Anna Bedbrook, L. Bertorello, Magnus Wickman, Marilyn Urrutia-Pereira, O. Spranger, René Maximiliano Gómez, C. Bachert, Renaud Louis, Musa Khaitov, C. Stellato, Constantinos Pitsios, Roland Buonaiuto, A. Romano, Sîan A Williams, R. Puy, Daniela Rivero-Yeverino, Y. Mohammad, J. Farrell, Jan Brozek, Ricardo Pio Monti, E. Paulino, J. Correia de Sousa, Miguel Alejandro Medina-Ávalos, Jocelyne Just, Peter Valentin Tomazic, Jean-François Ferrero, Antoine Magnan, S. Waserman, J Rosado-Pinto, Maciek Kupczyk, C.S. Bosnic-Anticevich, T. Dedeu, Tommi Vasankari, R. Mösges, Robin O'Hehir, Ema Paulino, Peter Hellings, A. Neou, M. Wickman, D. Lauri, Jean Bousquet, A. Ciceran, Jacques Bouchard, Yehia El-Gamal, M.G. Dominguez-Silva, M.R. Alberti, Jean-Louis Pépin, Kimi Okubo, Juan Carlos Ivancevich, Patrik Eklund, Benoit Pugin, C. Dario, Mussa Khaitov, Luisa Brussino, A.G. Chuchalin, Elísio Costa, Susanna Palkonen, Lars Münter, Pedro Carreiro-Martins, R.E. Pulido Ross, Ettore Novellino, Kai-Håkon Carlsen, María Antonieta Guzmán, G.W. Canonica, Gabriel Onorato, Giuseppe De Carlo, R.E. Roller-Wirnsberger, Brian J. Lipworth, M. A. Guzman, J.N. Tebyriçá, Adnan Custovic, Yoshitaka Okamoto, Rimantas Stukas, P. Manning, J. Sastre-Dominguez, Caroline L.S. George, Robyn E O'Hehir, K. Maciej, Bassam Mahboub, J. F. Fontaine, Arũnas Valiulis, Xavier Rodó, D. Vicheva, G. Canfora, Vitalis Briedis, S. Rodrigues Valle, Mark S. Dykewicz, Joanne Rimmer, G. Castellano, B. Pigearias, A. L. Boner, Yunuen Rocío Huerta-Villalobos, Christine Rolland, H. Neffen, H. Arshad, Javier Gómez-Vera, P. Moura Santo, Frederic Viart, F. Blasi, J. Garcia-Aymerich, Lorenzo Cecchi, V. Niedeberger, Giorgio Ciprandi, F. Caballero-Fonseca, Jean-François Fontaine, J Mullol, Maurizio Romano, M. Viegi, Mario E. Zernotti, Arunas Valiulis, Anna Asarnoj, Antonio Nieto, J. Lavrut, D. Dokic, V. Kvedariene, Ewa Jassem, Cezmi A. Akdis, Ruth Murray, Claus Bachert, Peter Schmid-Grendelmeier, Emilie Burte, Joaquim Mullol, Guido Iaccarino, J. Kleine-Tebbe, P. V. Tomazic, E. Eller, Alessandro Fiocchi, H.J. Schunemann, M. Sorlini, C. Robalo-Cordeiro, Ana-Maria Todo-Bom, J. Brozek, Marco Nalin, Matteo Bonini, J. C. Sisul, S.E. Dahlen, F. Amat, Juan Carlos Sisul, Jawad Hajjam, Ana Todo-Bom, Enrica Menditto, Bousquet J., Hellings P.W., Agache I., Amat F., Annesi-Maesano I., Ansotegui I.J., Anto J.M., Bachert C., Bateman E.D., Bedbrook A., Bennoor K., Bewick M., Bindslev-Jensen C., Bosnic-Anticevich S., Bosse I., Brozek J., Brussino L., Canonica G.W., Cardona V., Casale T., Cepeda Sarabia A.M., Chavannes N.H., Cecchi L., Correia de Sousa J., Costa E., Cruz A.A., Czarlewski W., De Carlo G., De Feo G., Demoly P., Devillier P., Dykewicz M.S., El-Gamal Y., Eller E.E., Fonseca J.A., Fontaine J.-F., Fokkens W.J., Guzman M.-A., Haahtela T., Illario M., Ivancevich J.-C., Just J., Kaidashev I., Khaitov M., Kalayci O., Keil T., Klimek L., Kowalski M.L., Kuna P., Kvedariene V., Larenas-Linnemann D., Laune D., Le L.T.T., Carlsen K.L., Lourenco O., Mahboub B., Mair A., Menditto E., Milenkovic B., Morais-Almeida M., Mosges R., Mullol J., Murray R., Naclerio R., Namazova-Baranova L., Novellino E., O'Hehir R.E., Ohta K., Okamoto Y., Okubo K., Onorato G.L., Palkonen S., Panzner P., Papadopoulos N.G., Park H.-S., Paulino E., Pawankar R., Pfaar O., Plavec D., Popov T.A., Potter P., Prokopakis E.P., Rottem M., Ryan D., Salimaki J., Samolinski B., Sanchez-Borges M., Schunemann H.J., Sheikh A., Sisul J.-C., Rajabian-Soderlund R., Sooronbaev T., Stellato C., To T., Todo-Bom A.-M., Tomazic P.-V., Toppila-Salmi S., Valero A., Valiulis A., Valovirta E., Ventura M.-T., Wagenmann M., Wang D.Y., Wallace D., Waserman S., Wickman M., Yorgancioglu A., Zhang L., Zhong N., Zidarn M., Zuberbier T., Aberer W., Akdis C.A., Akdis M., Alberti M.R., Almeida R., Angles R., Arnavielle S., Asayag E., Asarnoj A., Arshad H., Avolio F., Bacci E., Baiardini I., Barbara C., Barbagallo M., Baroni I., Barreto B.A., Basagana X., Bedolla-Barajas M., Beghe B., Bel E.H., Bergmann K.C., Benson M., Bertorello L., Bialoszewski A.Z., Bieber T., Bialek S., Bjermer L., Blain H., Blasi F., Blua A., Bochenska Marciniak M., Bogus-Buczynska I., Boner A.L., Bonini M., Bonini S., Bouchard J., Boulet L.P., Bourret R., Braido F., Briedis V., Brightling C.E., Bucca C., Buhl R., Buonaiuto R., Panaitescu C., Burguete Cabanas M.T., Burte E., Bush A., Caballero-Fonseca F., Caillot D., Caimmi D., Calderon M.A., Camargos P.A.M., Camuzat T., Canfora G., Carreiro-Martins P., Carriazo A.M., Carr W., Cartier C., Castellano G., Chen Y., Chiron R., Chivato T., Chkhartishvili E., Chuchalin A.G., Chung K.F., Ciaravolo M.M., Ciceran A., Cingi C., Ciprandi G., Carvalho Coehlo A.C., Colas L., Colgan E., Coll J., Conforti D., Cortes-Grimaldo R.M., Corti F., Costa-Dominguez M.C., Courbis A.L., Cox L., Crescenzo M., Custovic A., Dahlen S.E., Dario C., da Silva J., Dauvilliers Y., Darsow U., De Blay F., Dedeu T., de Fatima Emerson M., De Vries G., De Martino B., de Paula Motta Rubini N., Deleanu D., Denburg J.A., Di Capua Ercolano S., Di Carluccio N., Didier A., Dokic D., Dominguez-Silva M.G., Douagui H., Dray G., Dubakiene R., Durham S.R., Du Toit G., Eklund P., Emuzyte R., Farrell J., Farsi A., Ferreira de Mello J., Ferrero J., Fink-Wagner A., Fiocchi A., Forti S., Fuentes-Perez J.M., Galvez-Romero J.L., Gamkrelidze A., Garcia-Aymerich J., Garcia-Cobas C.Y., Garcia-Cruz M.H., Gemicioglu B., Genova S., George C., Gereda J.E., Gerth van Wijk R., Gomez R.M., Gomez-Vera J., Gonzalez Diaz S., Gotua M., Grisle I., Guidacci M., Guldemond N.A., Gutter Z., Hajjam J., Hernandez L., Hourihane J.O., Huerta-Villalobos Y.R., Humbert M., Iaccarino G., Jares E.J., Jassem E., Johnston S.L., Joos G., Jung K.S., Jutel M., Kalyoncu A.F., Karjalainen J., Kardas P., Keith P.K., Khaltaev N., Kleine-Tebbe J., Kuitunen M., Kull I., Kupczyk M., Krzych-Falta E., Lacwik P., Lauri D., Lavrut J., Lessa M., Levato G., Li J., Lieberman P., Lipiec A., Lipworth B., Lodrup Carlsen K.C., Louis R., Luna-Pech J.A., Maciej K., Magnan A., Maier D., Majer I., Malva J., Mandajieva E., Manning P., De Manuel Keenoy E., Marshall G.D., Masjedi M.R., Maspero J.F., Mathieu-Dupas E., Matta Campos J.J., Matos A.L., Maurer M., Mavale-Manuel S., Mayora O., Medina-Avalos M.A., Melen E., Melo-Gomes E., Meltzer E.O., Mercier J., Miculinic N., Mihaltan F., Moda G., Mogica-Martinez M.D., Mohammad Y., Momas I., Montefort S., Monti R., Mora Bogado D., Morato-Castro F.F., Mota-Pinto A., Moura Santo P., Munter L., Muraro A., Nadif R., Nalin M., Napoli L., Neffen H., Niedeberger V., Nekam K., Neou A., Nieto A., Nogueira-Silva L., Nogues M., Nyembue T.D., Odzhakova C., Ortega Cisneros M., Ouedraogo S., Pali-Scholl I., Papi A., Passalacqua G., Pedersen S., Pepin J.L., Pereira A.M., Persico M., Phillips J., Picard R., Pigearias B., Pin I., Pitsios C., Pohl W., Portejoie F., Pozzi A.C., Price D., Puy R., Pugin B., Pulido Ross R.E., Przemecka M., Rabe K.F., Raciborski F., Reitsma S., Ribeirinho I., Rimmer J., Rivero-Yeverino D., Rizzo J.A., Rizzo M.C., Robalo-Cordeiro C., Rodenas F., Rodo X., Rodriguez Gonzalez M., Rodriguez-Manas L., Rolland C., Rodrigues Valle S., Roman Rodriguez M., Romano A., Rodriguez-Zagal E., Rolla G., Roller-Wirnsberger R.E., Romano M., Rosado-Pinto J., Rosario N., Sagara H., Sastre-Dominguez J., Scadding G.K., Scichilone N., Schmid-Grendelmeier P., Serpa F.S., Shamai S., Sierra M., Simons F.E.R., Siroux V., Skrindo I., Sole D., Somekh D., Sondermann M., Sova M., Sorensen M., Sorlini M., Spranger O., Stelmach R., Stukas R., Sunyer J., Strozek J., Szylling A., Tebyrica J.N., Thibaudon M., Trama U., Triggiani M., Suppli Ulrik C., Urrutia-Pereira M., Valenta R., van Eerd M., van Ganse E., van Hague M., Vandenplas O., Vezzani G., Vasankari T., Vatrella A., Verissimo M.T., Viart F., Viegi M., Vicheva D., Vontetsianos T., Walker S., Werfel T., Westman M., Williams D.M., Williams S., Wilson N., Wright J., Wroczynski P., Yakovliev P., Yawn B.P., Yiallouros P.K., Yusuf O.M., Zar H.J., Zernotti M.E., Zubrinich C., Zurkuhlen A., Bousquet, Jean, Hellings, Peter W., Agache, Ioana, Amat, Flore, Annesi-Maesano, Isabella, Ansotegui, Ignacio J., Anto, Josep M., Bachert, Clau, Bateman, Eric D., Bedbrook, Anna, Bennoor, Kazi, Bewick, Mickael, Bindslev-Jensen, Carsten, Bosnic-Anticevich, Sinthia, Bosse, Isabelle, Brozek, Jan, Brussino, Luisa, Canonica, Giorgio W., Cardona, Victoria, Casale, Thoma, Cepeda Sarabia, Alfonso M., Chavannes, Niels H., Cecchi, Lorenzo, Correia de Sousa, Jaime, Costa, Elisio, Cruz, Alvaro A., Czarlewski, Wienczyslawa, De Carlo, Giuseppe, De Feo, Giulia, Demoly, Pascal, Devillier, Philippe, Dykewicz, Mark S., El-Gamal, Yehia, Eller, Esben E., Fonseca, Joao A., Fontaine, Jean-Françoi, Fokkens, Wytske J., Guzmán, Maria-Antonieta, Haahtela, Tari, Illario, Maddalena, Ivancevich, Juan-Carlo, Just, Jocelyne, Kaidashev, Igor, Khaitov, Musa, Kalayci, Omer, Keil, Thoma, Klimek, Ludger, Kowalski, Marek L., Kuna, Piotr, Kvedariene, Violeta, Larenas-Linnemann, Desiree, Laune, Daniel, Le, Lan T. T., Carlsen, Karin Lodrup, Lourenço, Olga, Mahboub, Bassam, Mair, Alpana, Menditto, Enrica, Milenkovic, Branislava, Morais-Almeida, Mario, Mösges, Ralph, Mullol, Joaquim, Murray, Ruth, Naclerio, Robert, Namazova-Baranova, Leyla, Novellino, Ettore, O'Hehir, Robyn E., Ohta, Ken, Okamoto, Yoshitaka, Okubo, Kimi, Onorato, Gabrielle L., Palkonen, Susanna, Panzner, Petr, Papadopoulos, Nikos G., Park, Hae-Sim, Paulino, Ema, Pawankar, Ruby, Pfaar, Oliver, Plavec, Davor, Popov, Ted A., Potter, Paul, Prokopakis, Emmanuel P., Rottem, Menachem, Ryan, Dermot, Salimäki, Johanna, Samolinski, Boleslaw, Sanchez-Borges, Mario, Schunemann, Holger J., Sheikh, Aziz, Sisul, Juan-Carlo, Rajabian-Söderlund, Rojin, Sooronbaev, Talant, Stellato, Cristiana, To, Teresa, Todo-Bom, Ana-Maria, Tomazic, Peter-Valentin, Toppila-Salmi, Sanna, Valero, Antonio, Valiulis, Aruna, Valovirta, Erkka, Ventura, Maria-Teresa, Wagenmann, Martin, Wang, De Yun, Wallace, Dana, Waserman, Susan, Wickman, Magnu, Yorgancioglu, Arzu, Zhang, Luo, Zhong, Nanshan, Zidarn, Mihaela, Zuberbier, Torsten, Bousquet, J., Hellings, P. W., Aberer, W., Agache, I., Akdis, C. A., Akdis, M., Alberti, M. R., Almeida, R., Amat, F., Angles, R., Annesi-Maesano, I., Ansotegui, I. J., Anto, J. M., Arnavielle, S., Asayag, E., Asarnoj, A., Arshad, H., Avolio, F., Bacci, E., Bachert, C., Baiardini, I., Barbara, C., Barbagallo, M., Baroni, I., Barreto, B. A., Basagana, X., Bateman, E. D., Bedolla-Barajas, M., Bedbrook, A., Bewick, M., Beghé, B., Bel, E. H., Bergmann, K. C., Bennoor, K. S., Benson, M., Bertorello, L., Białoszewski, A. Z., Bieber, T., Bialek, S., Bindslev-Jensen, C., Bjermer, L., Blain, H., Blasi, F., Blua, A., Bochenska Marciniak, M., Bogus-Buczynska, I., Boner, A. L., Bonini, M., Bonini, S., Bosnic-Anticevich, C. S., Bosse, I., Bouchard, J., Boulet, L. P., Bourret, R., Bousquet, P. J., Braido, F., Briedis, V., Brightling, C. E., Brozek, J., Bucca, C., Buhl, R., Buonaiuto, R., Panaitescu, C., Burguete Cabañas, M. T., Burte, E., Bush, A., Caballero-Fonseca, F., Caillot, D., Caimmi, D., Calderon, M. A., Camargos, P. A. M., Camuzat, T., Canfora, G., Canonica, G. W., Cardona, V., Carlsen, K. H., Carreiro-Martins, P., Carriazo, A. M., Carr, W., Cartier, C., Casale, T., Castellano, G., Cecchi, L., Cepeda Sarabia, A. M., Chavannes, N. H., Chen, Y., Chiron, R., Chivato, T., Chkhartishvili, E., Chuchalin, A. G., Chung, K. F., Ciaravolo, M. M., Ciceran, A., Cingi, C., Ciprandi, G., Carvalho Coehlo, A. C., Colas, L., Colgan, E., Coll, J., Conforti, D., Correia de Sousa, J., Cortés-Grimaldo, R. M., Corti, F., Costa, E., Costa-Dominguez, M. C., Courbis, A. L., Cox, L., Crescenzo, M., Cruz, A. A., Custovic, A., Czarlewski, W., Dahlen, S. E., Dario, C., da Silva, J., Dauvilliers, Y., Darsow, U., De Blay, F., De Carlo, G., Dedeu, T., de Fátima Emerson, M., De Feo, G., De Vries, G., De Martino, B., de Paula Motta Rubini, N., Deleanu, D., Demoly, P., Denburg, J. A., Devillier, P., Di Capua Ercolano, S., Di Carluccio, N., Didier, A., Dokic, D., Dominguez-Silva, M. G., Douagui, H., Dray, G., Dubakiene, R., Durham, S. R., Du Toit, G., Dykewicz, M. S., El-Gamal, Y., Eklund, P., Eller, E., Emuzyte, R., Farrell, J., Farsi, A., Ferreira de Mello, J., Ferrero, J., Fink-Wagner, A., Fiocchi, A., Fokkens, W. J., Fonseca, J. A., Fontaine, J. F., Forti, S., Fuentes-Perez, J. M., Gálvez-Romero, J. L., Gamkrelidze, A., Garcia-Aymerich, J., García-Cobas, C. Y., Garcia-Cruz, M. H., Gemicioğlu, B., Genova, S., George, C., Gereda, J. E., Gerth van Wijk, R., Gomez, R. M., Gómez-Vera, J., González Diaz, S., Gotua, M., Grisle, I., Guidacci, M., Guldemond, N. A., Gutter, Z., Guzmán, M. A., Haahtela, T., Hajjam, J., Hernández, L., Hourihane, J. O. 'B., Huerta-Villalobos, Y. R., Humbert, M., Iaccarino, G., Illario, M., Ivancevich, J. C., Jares, E. J., Jassem, E., Johnston, S. L., Joos, G., Jung, K. S., Jutel, M., Kaidashev, I., Kalayci, O., Kalyoncu, A. F., Karjalainen, J., Kardas, P., Keil, T., Keith, P. K., Khaitov, M., Khaltaev, N., Kleine-Tebbe, J., Klimek, L., Kowalski, M. L., Kuitunen, M., Kull, I., Kuna, P., Kupczyk, M., Kvedariene, V., Krzych-Fałta, E., Lacwik, P., Larenas-Linnemann, D., Laune, D., Lauri, D., Lavrut, J., Le, L. T. T., Lessa, M., Levato, G., Li, J., Lieberman, P., Lipiec, A., Lipworth, B., Lodrup Carlsen, K. C., Louis, R., Lourenço, O., Luna-Pech, J. A., Maciej, K., Magnan, A., Mahboub, B., Maier, D., Mair, A., Majer, I., Malva, J., Mandajieva, E., Manning, P., De Manuel Keenoy, E., Marshall, G. D., Masjedi, M. R., Maspero, J. F., Mathieu-Dupas, E., Matta Campos, J. J., Matos, A. L., Maurer, M., Mavale-Manuel, S., Mayora, O., Medina-Avalos, M. A., Melén, E., Melo-Gomes, E., Meltzer, E. O., Menditto, E., Mercier, J., Miculinic, N., Mihaltan, F., Milenkovic, B., Moda, G., Mogica-Martinez, M. D., Mohammad, Y., Momas, I., Montefort, S., Monti, R., Mora Bogado, D., Morais-Almeida, M., Morato-Castro, F. F., Mösges, R., Mota-Pinto, A., Moura Santo, P., Mullol, J., Münter, L., Muraro, A., Murray, R., Naclerio, R., Nadif, R., Nalin, M., Napoli, L., Namazova-Baranova, L., Neffen, H., Niedeberger, V., Nekam, K., Neou, A., Nieto, A., Nogueira-Silva, L., Nogues, M., Novellino, E., Nyembue, T. D., O'Hehir, R. E., Odzhakova, C., Ohta, K., Okamoto, Y., Okubo, K., Onorato, G. L., Ortega Cisneros, M., Ouedraogo, S., Pali-Schöll, I., Palkonen, S., Panzner, P., Papadopoulos, N. G., Park, H. S., Papi, A., Passalacqua, G., Paulino, E., Pawankar, R., Pedersen, S., Pépin, J. L., Pereira, A. M., Persico, M., Pfaar, O., Phillips, J., Picard, R., Pigearias, B., Pin, I., Pitsios, C., Plavec, D., Pohl, W., Popov, T. A., Portejoie, F., Potter, P., Pozzi, A. C., Price, D., Prokopakis, E. P., Puy, R., Pugin, B., Pulido Ross, R. E., Przemecka, M., Rabe, K. F., Raciborski, F., Rajabian-Soderlund, R., Reitsma, S., Ribeirinho, I., Rimmer, J., Rivero-Yeverino, D., Rizzo, J. A., Rizzo, M. C., Robalo-Cordeiro, C., Rodenas, F., Rodo, X., Rodriguez Gonzalez, M., Rodriguez-Mañas, L., Rolland, C., Rodrigues Valle, S., Roman Rodriguez, M., Romano, A., Rodriguez-Zagal, E., Rolla, G., Roller-Wirnsberger, R. E., Romano, M., Rosado-Pinto, J., Rosario, N., Rottem, M., Ryan, D., Sagara, H., Salimäki, J., Samolinski, B., Sanchez-Borges, M., Sastre-Dominguez, J., Scadding, G. K., Schunemann, H. J., Scichilone, N., Schmid-Grendelmeier, P., Serpa, F. S., Shamai, S., Sheikh, A., Sierra, M., Simons, F. E. R., Siroux, V., Sisul, J. C., Skrindo, I., Solé, D., Somekh, D., Sondermann, M., Sooronbaev, T., Sova, M., Sorensen, M., Sorlini, M., Spranger, O., Stellato, C., Stelmach, R., Stukas, R., Sunyer, J., Strozek, J., Szylling, A., Tebyriçá, J. N., Thibaudon, M., To, T., Todo-Bom, A., Tomazic, P. V., Toppila-Salmi, S., Trama, U., Triggiani, M., Suppli Ulrik, C., Urrutia-Pereira, M., Valenta, R., Valero, A., Valiulis, A., Valovirta, E., van Eerd, M., van Ganse, E., van Hague, M., Vandenplas, O., Ventura, M. T., Vezzani, G., Vasankari, T., Vatrella, A., Verissimo, M. T., Viart, F., Viegi, M., Vicheva, D., Vontetsianos, T., Wagenmann, M., Walker, S., Wallace, D., Wang, D. Y., Waserman, S., Werfel, T., Westman, M., Wickman, M., Williams, D. M., Williams, S., Wilson, N., Wright, J., Wroczynski, P., Yakovliev, P., Yawn, B. P., Yiallouros, P. K., Yorgancioglu, A., Yusuf, O. M., Zar, H. J., Zhang, L., Zhong, N., Zernotti, M. E., Zidarn, M., Zuberbier, T., Zubrinich, C., Zurkuhlen, A., CHU Montpellier, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Contre les MAladies Chroniques pour un VIeillissement Actif en Languedoc-Roussillon (MACVIA-LR), Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Universitaire de Nîmes (CHU Nîmes)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS)-European Innovation Partnership on Active and Healthy Ageing Reference Site (EIP on AHA), Commission Européenne-Commission Européenne-Organisation Mondiale de la Santé / World Health Organization Office (OMS / WHO), Vieillissement et Maladies chroniques : approches épidémiologique et de santé publique (VIMA), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Institut National de la Santé et de la Recherche Médicale (INSERM), European Forum for Research and Education in Allergy and Airway Diseases (EUFOREA), Catholic University of Leuven - Katholieke Universiteit Leuven (KU Leuven), Laboratory of clinical immunology, Department of Allergy and Clinical Immunology, Transylvania University of Brasov, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Epidémiologie, Systèmes d'Information, Modélisation, Université Pierre et Marie Curie - Paris 6 (UPMC)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), Epidemiology of Allergic and Respiratory Diseases Department [iPlesp] (EPAR), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Department of Allergy and Immunology, Hospital Quirónsalud Bizkaia [Bilbao], Center for Research in Environmental Epidemiology (CREAL), Universitat Pompeu Fabra [Barcelona] (UPF)-Catalunya ministerio de salud, Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Hacettepe University = Hacettepe Üniversitesi, Mechanobiology Institute [Singapore] (MBI), National University of Singapore (NUS), Department of Clinical Epidemiology and Biostatistics and Medicine, McMaster University [Hamilton, Ontario], Department of Dermatology [Graz, Austria], Medical University Graz, Swiss Institute of Allergy and Asthma Research (SIAF), Universität Zürich [Zürich] = University of Zurich (UZH), Department Engineering Quimica (ICEMS), Ghent University Hospital, Istituto Nazionale di Fisica Nucleare, sezione di Bari (INFN, sezione di Bari), Istituto Nazionale di Fisica Nucleare (INFN), IMIM-Hospital del Mar, Generalitat de Catalunya, University of Cape Town, Divisions of Human Genetics Infection, Inflammation and Repair, University of Southampton-School of Medicine, Centre de gérontologie, Department of Pathophysiology and Transplantation, Università degli Studi di Milano = University of Milan (UNIMI), Istituto di Geoscienze e Georisorse, Pavia, Institute of Neurobiology and Molecular Medicine, CNR, Rome, Italy and Department of Medicine-University of Naples Federico II = Università degli studi di Napoli Federico II, Woolcock Institute of Medical Research [Sydney], The University of Sydney, Université Laval [Québec] (ULaval), Departments of Clinical Epidemiology and Biostatistics and Medicine [Ontario], Service greffe de moelle osseuse, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Département pneumologie et addictologie [Montpellier], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Hôpital Arnaud de Villeneuve, Royal Brompton Hospital, Région Languedoc-Roussillon-Midi-Pyrénées, Vall d'Hebron University Hospital [Barcelona], University of South Florida [Tampa] (USF), Università degli Studi di Firenze = University of Florence (UniFI), University of Michigan, Department of Atmospheric, Centres de Ressources et de Compétences de la Mucoviscidose [Montpellier] (CRCM [Montpellier]), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Hôpital Arnaud de Villeneuve-Service des Maladies Respiratoires, Russian State Medical University, Universidade do Porto, Instituto de Biologia Molecular e Celular (IBMC), UCB Pharma, Colombes, Hôpital Gui de Chauliac [CHU Montpellier], CHU Strasbourg, European Federation of Allergy (EFA), Airways Diseases Patients' Associations, Università degli Studi di Salerno = University of Salerno (UNISA), Laboratoire de recherche sur les mécanismes moléculaires et pharmacologiques de l’obstruction bronchique (LOBIP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), Laboratoire de Génie Informatique et Ingénierie de Production (LGI2P), IMT - MINES ALES (IMT - MINES ALES), Institut Mines-Télécom [Paris] (IMT)-Institut Mines-Télécom [Paris] (IMT), Linköping University (LIU), Department of Dermatology and Allergy Centre, Odense University Hospital, Vilnius University [Vilnius], Center of Research in Health Technologies and Information Systems (CINTESIS), Universidade do Porto = University of Porto, Institut d'Electronique du Solide et des Systèmes (InESS), Centre National de la Recherche Scientifique (CNRS), Son Pisa Primary Care Centre, IB-Salut Balearic Health Service, Center for Allergy and Immunology Research [Tbilisi], Department of Dermatology, Helsinki University Hospital-Skin and Allergy Hospital, Swedish Meteorological and Hydrological Institute (SMHI), CORYSS-TESS, Ukrainina Medical Stomatological Academy [Poltava, Ukraine], Institute of Social Medicine, Epidemiology and Health Economics-Charité - UniversitätsMedizin = Charité - University Hospital [Berlin], Biologie des organismes marins et écosystèmes (BOME), Muséum national d'Histoire naturelle (MNHN)-Université Pierre et Marie Curie - Paris 6 (UPMC)-Centre National de la Recherche Scientifique (CNRS), NRC Institute of immunology FMBA, Moscow Russian federation, Allergy and Asthma Center Westend, German Society for Otorhinolaryngology HNS, Rheinische Friedrich-Wilhelms-Universität Bonn, The Institute of Environmental Medicine [Stockholm] (IMM), Karolinska Institutet [Stockholm], Medical University of Łódź (MUL), Hospital Medica Sur, Institut de Recherche en Infectiologie de Montpellier (IRIM), Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), Applied Physical Chemistry Laboratory (APCLab), Institute of Geophysics and Planetary Physics [Los Angeles] (IGPP), University of California [Los Angeles] (UCLA), University of California (UC)-University of California (UC), Équipe de Recherche en Textes, Informatique, Multilinguisme (ERTIM), Institut National des Langues et Civilisations Orientales (Inalco), Institute of Oceanology [China], University of Beira Interior [Portugal] (UBI), Unité de recherche de l'institut du thorax (ITX-lab), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN), Pulmonary and allergy unit, American University of Sharjah-Rashid Hospital-Dubai Health Authority (DHA), Astrophysique Interprétation Modélisation (AIM (UMR7158 / UMR_E_9005 / UM_112)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Institut national des sciences de l'Univers (INSU - CNRS)-Université Paris Diderot - Paris 7 (UPD7)-Centre National de la Recherche Scientifique (CNRS), Sysdiag-Modélisation et Ingénierie des Systèmes Complexes Biologiques pour le Diagnostic (SysDiag ), BIO-RAD-Centre National de la Recherche Scientifique (CNRS), 'Federico II' University of Naples Medical School, Physiologie & médecine expérimentale du Cœur et des Muscles [U 1046] (PhyMedExp), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), Pneumology Department, Marius Nasta Institute of Pneumology, Department of Prevention of Environmental Hazards and Allergology, Medical University of Warsaw - Poland-Faculté de Pharmacie de Paris, Allergy and Clinical Immunology Department, Hospital CUF Descobertas, Universität zu Köln = University of Cologne, Centro de Investigación Biomédica en Red Enfermedades Respiratorias (CIBERES), Section of Otolaryngology-Head & Neck Surgery (OHNS), University of Chicago, Department of Pharmacy Naples, Université de Naples, Department of Allergy, Immunology and Respiratory Medicine, Alfred Hospital-Monash University Building, AMREP, Dept. of Electronic Engineering, Chubu University, Department of Otorhinolaryngology, Chiba University Hospital, Department of Allergology and Clinical Immunology, Charles University [Prague] (CU)-Medical Faculty in Pilsen, Department of Earth and Planetary Sciences [Cambridge, USA] (EPS), Harvard University, Allergy and Respiratory Diseases, Università degli studi di Genova = University of Genoa (UniGe), Department of Pediatrics, Nippon Medical School, Centre Hospitalier Universitaire [Grenoble] (CHU), Department of Otorhinolaryngology, Head and Neck Surgery [Mannheim, Germany], University Hospital Mannheim, Laboratoire de physique et chimie des nano-objets (LPCNO), Institut National des Sciences Appliquées - Toulouse (INSA Toulouse), Institut National des Sciences Appliquées (INSA)-Université de Toulouse (UT)-Institut National des Sciences Appliquées (INSA)-Université de Toulouse (UT)-Institut de Chimie de Toulouse (ICT), Institut de Recherche pour le Développement (IRD)-Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Institut National Polytechnique (Toulouse) (Toulouse INP), Université de Toulouse (UT)-Institut de Recherche pour le Développement (IRD)-Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Institut National Polytechnique (Toulouse) (Toulouse INP), Université de Toulouse (UT)-Institut de Recherche sur les Systèmes Atomiques et Moléculaires Complexes (IRSAMC), Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université de Toulouse (UT)-Centre National de la Recherche Scientifique (CNRS)-Centre National de la Recherche Scientifique (CNRS), CHU Grenoble, Children’s Hospital Srebrnjak [Zagreb, Croatia], Department of Physics [UMIST Manchester], University of Manchester Institute of Science and Technology (UMIST), Laboratori Nazionali del Sud (LNS), Getafe University Hospital, Madrid, Karl-Franzens-Universität Graz, Ecologie comportementale (EC), École normale supérieure - Paris (ENS-PSL), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Institut National de la Recherche Agronomique (INRA)-Université Montpellier 2 - Sciences et Techniques (UM2)-Université Paris-Sud - Paris 11 (UP11)-Université Pierre et Marie Curie - Paris 6 (UPMC)-Université de Rennes (UR)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université de Bourgogne (UB)-Centre National de la Recherche Scientifique (CNRS), Allergy Asthma and Immunology [Haifa, Israel], Ha'Emek Medical Center, Afula-Rappaport Faculty of Medicine, University of Edinburgh, Medical University of Warsaw - Poland, Department of Allergy and Clinical Immunology [Caracas, Venezuela], Centro Médico Docente La Trinidad, Department of Computer Science [Haifa], University of Haifa [Haifa], Allergy and Respiratory Research Group, Institut d'oncologie/développement Albert Bonniot de Grenoble (INSERM U823), Université Joseph Fourier - Grenoble 1 (UJF)-CHU Grenoble-EFS-Institut National de la Santé et de la Recherche Médicale (INSERM), National Centre of Cardiology and Internal Medicine, Ministry of Health Kyrgyz Republic, Réseau National de Surveillance Aérobiologique (RNSA), Berkeley Seismological Laboratory, Division of Clinical Immunology and Allergy, University of Naples Federico II = Università degli studi di Napoli Federico II, CIRCE, Ctr Res Energy Resources & Consumpt, Zaragoza 50018, Spain, Vilnius University Clinic of Children's Diseases, Suomen Terveystalo Allergy Clinic, Health Service and Performance Research (HESPER), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon, Centre d'EPistémologie et d'ERgologie Comparatives (CEPERC), Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS), Institute for Climate and Atmospheric Science [Leeds] (ICAS), School of Earth and Environment [Leeds] (SEE), University of Leeds-University of Leeds, Nova Southeastern University (NSU), Department of Otolaryngology, National University of Singapore (NUS)-Yong Loo Lin School of Medicine, Sachs' Children's Hospital, IAES, Department of Pulmonology, Manisa Celal Bayar University, Center for Evolutionary and Theoretical Immunology [Albuquerque, New Mexico] (CETI), The University of New Mexico [Albuquerque], National Key State Laboratory for ThermoStructural Composites (TSCM), Northwestern Polytechnical University [Xi'an] (NPU), Respiratory and Allergic Diseases, University Clinic of Respiratory and Allergic Diseases Golnik, University Hospital of Cologne [Cologne], Supported by the European Innovation Partnership on Active and Healthy Ageing and POLLAR (EIT Health, European Union)., European Project: 643803,H2020,H2020-HCO-2014,PROEIPAHA(2015), UCL - (MGD) Service de pneumologie, UCL - SSS/IREC/PNEU - Pôle de Pneumologie, ORL et Dermatologie, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Université Montpellier 1 (UM1)-Centre Hospitalier Universitaire de Nîmes (CHU Nîmes)-European Innovation Partnership on Active and Healthy Ageing Reference Site (EIP on AHA), Commission Européenne-Commission Européenne-Organisation Mondiale de la Santé / World Health Organization Office (OMS / WHO)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Epidemiology of Allergic and Respiratory Diseases Department [Paris] (EPAR), Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Hospital Quiròn Bizkaia Erandio, Université Pierre et Marie Curie - Paris 6 (UPMC), University of Milan, University of Naples Federico II-CNR, Rome, Italy and Department of Medicine, Université Paris Diderot - Paris 7 (UPD7)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Università degli Studi di Firenze = University of Florence [Firenze] (UNIFI), Hôpital Gui de Chauliac, Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Università degli Studi di Salerno (UNISA), Institut de Physique du Globe de Paris (IPGP), Centre National de la Recherche Scientifique (CNRS)-Université de La Réunion (UR)-Université Paris Diderot - Paris 7 (UPD7)-IPG PARIS-Institut national des sciences de l'Univers (INSU - CNRS), Charité - UniversitätsMedizin = Charité - University Hospital [Berlin]-Epidemiology and Health Economics, Centre National de la Recherche Scientifique (CNRS)-Université Pierre et Marie Curie - Paris 6 (UPMC)-Muséum national d'Histoire naturelle (MNHN), University of California-University of California, unité de recherche de l'institut du thorax UMR1087 UMR6291 (ITX), Astrophysique Interprétation Modélisation (AIM (UMR_7158 / UMR_E_9005 / UM_112)), Centre National de la Recherche Scientifique (CNRS)-Institut national des sciences de l'Univers (INSU - CNRS)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris Diderot - Paris 7 (UPD7), Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Hospital CUF-Descobertas, Universität zu Köln, Medical Faculty in Pilsen-Charles University in Prague - the First Faculty of Medicine, Harvard University [Cambridge], University of Genoa (UNIGE), Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Institut de Chimie de Toulouse (ICT-FR 2599), Institut National Polytechnique (Toulouse) (Toulouse INP), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Institut de Chimie du CNRS (INC)-Institut National Polytechnique (Toulouse) (Toulouse INP), Université Fédérale Toulouse Midi-Pyrénées-Institut de Chimie du CNRS (INC)-Institut de Recherche sur les Systèmes Atomiques et Moléculaires Complexes (IRSAMC), Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Centre National de la Recherche Scientifique (CNRS)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS), University of Graz, École normale supérieure - Paris (ENS Paris), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Institut National de la Recherche Agronomique (INRA)-Université Montpellier 2 - Sciences et Techniques (UM2)-Université Paris-Sud - Paris 11 (UP11)-Université Pierre et Marie Curie - Paris 6 (UPMC)-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Université Claude Bernard Lyon 1 (UCBL), Centro Medico-Docente La Trinidad, Institut National de la Santé et de la Recherche Médicale (INSERM)-EFS-CHU Grenoble-Université Joseph Fourier - Grenoble 1 (UJF), Università degli studi di Napoli Federico II, Center for Evolutionary and theoretical Immunology, Biology, National Institute for Health Research, CNR, Rome, Italy and Department of Medicine-University of Naples Federico II, Institut national des sciences de l'Univers (INSU - CNRS)-IPG PARIS-Université Paris Diderot - Paris 7 (UPD7)-Université de La Réunion (UR)-Centre National de la Recherche Scientifique (CNRS), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Institut National Polytechnique (Toulouse) (Toulouse INP), Université Fédérale Toulouse Midi-Pyrénées-Institut de Recherche pour le Développement (IRD)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Institut de Recherche sur les Systèmes Atomiques et Moléculaires Complexes (IRSAMC), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS)-Centre National de la Recherche Scientifique (CNRS), Karl-Franzens-Universität [Graz, Autriche], Department of Dermatology, Allergology and Venereology, Clinicum, University of Helsinki, Children's Hospital, Faculty of Law, HUS Children and Adolescents, HUS Inflammation Center, University Hospitals Leuven [Leuven], Universitat Pompeu Fabra [Barcelona]-Catalunya ministerio de salud, University of Zürich [Zürich] (UZH), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), University of South Florida (USF), Università degli Studi di Firenze = University of Florence [Firenze], Laboratoire Magmas et Volcans (LMV), Observatoire de Physique du Globe de Clermont-Ferrand (OPGC), Université Blaise Pascal - Clermont-Ferrand 2 (UBP)-Institut national des sciences de l'Univers (INSU - CNRS)-Centre National de la Recherche Scientifique (CNRS)-Université Blaise Pascal - Clermont-Ferrand 2 (UBP)-Institut national des sciences de l'Univers (INSU - CNRS)-Centre National de la Recherche Scientifique (CNRS)-Université Jean Monnet [Saint-Étienne] (UJM)-Centre National de la Recherche Scientifique (CNRS), Universidade do Porto [Porto], Charité - Universitätsmedizin Berlin / Charite - University Medicine Berlin -Epidemiology and Health Economics, Université Pierre et Marie Curie - Paris 6 (UPMC)-Muséum national d'Histoire naturelle (MNHN)-Centre National de la Recherche Scientifique (CNRS), Centre National de la Recherche Scientifique (CNRS)-Université de Montpellier (UM), Centre de Biologie pour la Gestion des Populations (UMR CBGP), Centre de Coopération Internationale en Recherche Agronomique pour le Développement (Cirad)-Institut National de la Recherche Agronomique (INRA)-Centre international d'études supérieures en sciences agronomiques (Montpellier SupAgro)-Université de Montpellier (UM)-Institut de Recherche pour le Développement (IRD [France-Sud])-Institut national d’études supérieures agronomiques de Montpellier (Montpellier SupAgro), Institut national d'enseignement supérieur pour l'agriculture, l'alimentation et l'environnement (Institut Agro)-Institut national d'enseignement supérieur pour l'agriculture, l'alimentation et l'environnement (Institut Agro), Sondra, CentraleSupélec, Université Paris-Saclay (COmUE) (SONDRA), ONERA-CentraleSupélec-Université Paris Saclay (COmUE), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut de Recherche pour le Développement (IRD)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS)-Institut National Polytechnique (Toulouse) (Toulouse INP), Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche sur les Systèmes Atomiques et Moléculaires Complexes (IRSAMC), Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Université Toulouse III - Paul Sabatier (UT3), RNSA, Centre d'EPistémologie et d'ERgologie Comparatives - UMR 7304 (CEPERC), Centre National de la Recherche Scientifique (CNRS)-Aix Marseille Université (AMU), Ear, Nose and Throat, AII - Inflammatory diseases, Pulmonology, Institut de Recherche sur les Systèmes Atomiques et Moléculaires Complexes (IRSAMC), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National des Sciences Appliquées - Toulouse (INSA Toulouse), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut de Chimie de Toulouse (ICT-FR 2599), Université Fédérale Toulouse Midi-Pyrénées-Institut de Recherche pour le Développement (IRD)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Institut National Polytechnique (Toulouse) (Toulouse INP), Université Fédérale Toulouse Midi-Pyrénées, Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Régional Universitaire de Nîmes (CHRU Nîmes)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS)-European Innovation Partnership on Active and Healthy Ageing Reference Site (EIP on AHA), National Institute for Nuclear Physics (INFN), Université Laval, Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Université Paris Diderot - Paris 7 (UPD7)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), Università degli Studi di Firenze [Firenze], University of Salerno (UNISA), Centre National de la Recherche Scientifique (CNRS)-Université Jean Monnet [Saint-Étienne] (UJM)-Institut national des sciences de l'Univers (INSU - CNRS)-Université Blaise Pascal - Clermont-Ferrand 2 (UBP)-Observatoire de Physique du Globe de Clermont-Ferrand (OPGC), Centre National de la Recherche Scientifique (CNRS)-Institut national des sciences de l'Univers (INSU - CNRS)-Université Blaise Pascal - Clermont-Ferrand 2 (UBP)-Centre National de la Recherche Scientifique (CNRS), Université Pierre et Marie Curie - Paris 6 (UPMC)-Centre National de la Recherche Scientifique (CNRS), Sondra, CentraleSupélec, Université Paris-Saclay (SONDRA), ONERA-CentraleSupélec-Université Paris-Saclay, Centre National de la Recherche Scientifique (CNRS)-Institut National des Sciences Appliquées - Toulouse (INSA Toulouse), École normale supérieure - Paris (ENS Paris)-Institut National de la Recherche Agronomique (INRA)-Université Montpellier 2 - Sciences et Techniques (UM2)-Université Paris-Sud - Paris 11 (UP11)-Université Pierre et Marie Curie - Paris 6 (UPMC)-Université de Rennes 1 (UR1), Universidade do Minho, İÜC, Cerrahpaşa Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, uBibliorum, and Internal Medicine
- Subjects
Allergy ,Medicina Básica [Ciências Médicas] ,asthma -- guideline ,Allergic asthma ,DECISION-MAKING ,Allergic Rhinitis and Its Impact on Asthma ,GUIDELINES ,Medical and Health Sciences ,Medical Records ,0302 clinical medicine ,Health care ,Immunology and Allergy ,030212 general & internal medicine ,asthma ,Change management ,rhinitis ,Immunology ,MASK-RHINITIS ,ComputingMilieux_MISCELLANEOUS ,Rinitis ,mobilne aplikacije ,upravljanje sprememb ,Medical record ,GLOBAL STRATEGY ,WORK PRODUCTIVITY ,Telemedicine ,mobile applications ,3. Good health ,Asma alérgica ,rhiniti ,1107 Immunology ,Ciências Médicas::Medicina Básica ,klinične poti ,allergic -- guideline ,Life Sciences & Biomedicine ,Human ,PATIENT PARTICIPATION ,Allergic Rhinitis ,medicine.medical_specialty ,animal structures ,multimorbidity ,EUROPEAN INNOVATION PARTNERSHIP ,Change Management ,[object Object] ,Settore MED/10 - Malattie Dell'Apparato Respiratorio ,Asthma/diagnosis ,CHRONIC DISEASES ,MACVIA-ARIA ,03 medical and health sciences ,medicine ,multimorbidnost ,QUALITY ,Humans ,critical pathways ,astma -- smernica ,Patient participation ,Asma ,udc:616.2 ,Asthma ,Science & Technology ,ARIA ,business.industry ,Multimorbidity ,Rhinitis, Allergic ,Settore MED/09 - MEDICINA INTERNA ,change management ,Mobile Airways Sentinel Network (MASK) Study Group ,Guideline ,ta3121 ,medicine.disease ,Rinite alérgica ,Rhinitis, Allergic/diagnosis ,Integrated care ,alergijski rinitis -- smernica ,Allergic Rhinitis and Its Impact on Asthma, asthma, Change management, rhinitis, Immunology and Allergy, Immunology ,030228 respiratory system ,Family medicine ,3121 General medicine, internal medicine and other clinical medicine ,Medical Record ,Clinical Medicine ,business ,[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology ,Impact on Asthma - Abstract
Allergic Rhinitis and its Impact on Asthma (ARIA) has evolved from a guideline by using the best approach to integrated care pathways using mobile technology in patients with allergic rhinitis (AR) and asthma multimorbidity. The proposed next phase of ARIA is change management, with the aim of providing an active and healthy life to patients with rhinitis and to those with asthma multimorbidity across the lifecycle irrespective of their sex or socioeconomic status to reduce health and social inequities incurred by the disease. ARIA has followed the 8-step model of Kotter to assess and implement the effect of rhinitis on asthma multimorbidity and to propose multimorbid guidelines. A second change management strategy is proposed by ARIA Phase 4 to increase self-medication and shared decision making in rhinitis and asthma multimorbidity. An innovation of ARIA has been the development and validation of information technology evidence-based tools (Mobile Airways Sentinel Network [MASK]) that can inform patient decisions on the basis of a self-care plan proposed by the health care professional., EAACI -European Academy of Allergy and Clinical Immunology(undefined), info:eu-repo/semantics/acceptedVersion
- Published
- 2018
29. Empowering Translation of New Ideas - A EIT Health ClinMed Summer School Overview
- Author
-
Isabelle Marque, Dimitrios I. Zeugolis, Sofia Ribeiro, Lionel Pazart, Sylvia Pelayo, Albert Von Der Lieth, Mariachiara Ricci, Yves Bayon, EIT-Health, Seventh Framework Programme, and Horizon 2020
- Subjects
Medical device ,European community ,4. Education ,ClinMed Summer School ,Library science ,02 engineering and technology ,010402 general chemistry ,021001 nanoscience & nanotechnology ,01 natural sciences ,Categorical grant ,Innovation by Design ,0104 chemical sciences ,Marie curie ,Work (electrical) ,Medical Device ,Training ,Sociology ,EIT Health ,0210 nano-technology - Abstract
Translational research training is crucial to convert academic research ideas into efficient real-life solutions. In this paper a summer school supported by EIT Health is presented. Its main goal is to integrate clinical knowledge in the development of new medical devices, from ideas to post-market approval, in the clinics. Students were immersed in clinical centres where they had close contacts and engaged discussions with clinicians and patients to identify and assimilate clinical unmet needs. From this immersive stage resulted innovative solutions that were further investigated with the support of plenary lectures and by interaction with experts of the medical field, from clinicians to Medtech company representatives. This experience proved to have a positive impact on the student’s understanding of the clinical development life cycle from research findings or new ideas into medical devices. This work received funding from EIT-Health campus call (Project Grant Agreement n°18497). This research was supported by a Marie Curie ITN fellowship within the 7th European Community Framework Programme (Grant Number: 676338). Not
- Full Text
- View/download PDF
30. DECONbench: a benchmarking platform dedicated to deconvolution methods for tumor heterogeneity quantification
- Author
-
Decamps, Clémentine, Arnaud, Alexis, Petitprez, Florent, Ayadi, Mira, Baurès, Aurélia, Armenoult, Lucile, Alcala, N., Arnaud, A., Avila Cobos, Francisco, Batista, Luciana, Batto, A.-F., Blum, Y., Chuffart, F., Cros, J., Decamps, C., Dirian, L., Doncevic, D., Durif, G., Bahena Hernandez, S. Y., Jakobi, M., Jardillier, R., Jeanmougin, M., Jedynak, P., Jumentier, B., Kakoichankava, A., Kondili, Maria, Liu, J., Maie, T., Marécaille, J., Merlevede, J., Meylan, M., Nazarov, P., Newar, K., Nyrén, K., Petitprez, F., Novella Rausell, C., Richard, M., Scherer, M., Sompairac, N., Waury, K., Xie, T., Zacharouli, M.-A., Escalera, Sergio, Guyon, Isabelle, Nicolle, Rémy, Tomasini, Richard, de Reyniès, Aurélien, Cros, Jérôme, Blum, Yuna, Richard, Magali, HADACA consortium, [missing], Translational Innovation in Medicine and Complexity / Recherche Translationnelle et Innovation en Médecine et Complexité - UMR 5525 (TIMC ), VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes (UGA)-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP ), Université Grenoble Alpes (UGA), Ligue Nationale Contre le Cancer - Paris, Ligue Nationnale Contre le Cancer, University of Barcelona, Laboratoire Interdisciplinaire des Sciences du Numérique (LISN), CentraleSupélec-Université Paris-Saclay-Centre National de la Recherche Scientifique (CNRS), A&O (Apprentissage et Optimisation) (A&O), CentraleSupélec-Université Paris-Saclay-Centre National de la Recherche Scientifique (CNRS)-CentraleSupélec-Université Paris-Saclay-Centre National de la Recherche Scientifique (CNRS)-Science des Données (SDD), CentraleSupélec-Université Paris-Saclay-Centre National de la Recherche Scientifique (CNRS)-CentraleSupélec-Université Paris-Saclay-Centre National de la Recherche Scientifique (CNRS)-Algorithmes, Apprentissage et Calcul (AAC), CentraleSupélec-Université Paris-Saclay-Centre National de la Recherche Scientifique (CNRS)-CentraleSupélec-Université Paris-Saclay-Centre National de la Recherche Scientifique (CNRS), Centre de Recherche en Cancérologie de Marseille (CRCM), Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Aix Marseille Université (AMU), Institut de Génétique et Développement de Rennes (IGDR), Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )-Centre National de la Recherche Scientifique (CNRS)-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES), The research leading to these results was supported by Univ. Grenoble-Alpes via the Grenoble Alpes Data Institute [MR, AA] (ANR-15-IDEX-02), EIT Health Campus HADACA and COMETH programs [MR, YB], activities 19359 and 20377 and the Ligue Nationale Contre le Cancer. Other fundings: South-Eastern Norway Regional Health Authority (project number 2019030 [MJ]), European IMI IMMUCAN project [NS], European Union's Horizon 2020 program (Grant 826121, iPC project, [JM, FAC]). This article did not receive specific sponsorship in the design of the study, analysis, interpretation of data and in writing the manuscript., ANR-15-IDEX-0002,UGA,IDEX UGA(2015), European Project: 826121,iPaediatricCurie, Biologie Computationnelle et Modélisation (TIMC-BCM ), Université Grenoble Alpes (UGA)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes (UGA)-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP ), Ligue Nationale Contre le Cancer (LNCC), Institut National de Recherche en Informatique et en Automatique (Inria)-CentraleSupélec-Université Paris-Saclay-Centre National de la Recherche Scientifique (CNRS), Institut National de Recherche en Informatique et en Automatique (Inria)-CentraleSupélec-Université Paris-Saclay-Centre National de la Recherche Scientifique (CNRS)-Institut National de Recherche en Informatique et en Automatique (Inria)-CentraleSupélec-Université Paris-Saclay-Centre National de la Recherche Scientifique (CNRS)-Science des Données (SDD), Institut National de Recherche en Informatique et en Automatique (Inria)-CentraleSupélec-Université Paris-Saclay-Centre National de la Recherche Scientifique (CNRS)-Institut National de Recherche en Informatique et en Automatique (Inria)-CentraleSupélec-Université Paris-Saclay-Centre National de la Recherche Scientifique (CNRS)-Algorithmes, Apprentissage et Calcul (AAC), Institut National de Recherche en Informatique et en Automatique (Inria)-CentraleSupélec-Université Paris-Saclay-Centre National de la Recherche Scientifique (CNRS)-Institut National de Recherche en Informatique et en Automatique (Inria)-CentraleSupélec-Université Paris-Saclay-Centre National de la Recherche Scientifique (CNRS), Aix Marseille Université (AMU)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Université de Rennes (UR)-Centre National de la Recherche Scientifique (CNRS)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Richard, Magali, IDEX UGA - - UGA2015 - ANR-15-IDEX-0002 - IDEX - VALID, and European Union’s Horizon 2020 program (grant No. 826121, iPC project) - iPaediatricCurie - 826121 - INCOMING
- Subjects
Classificació de tumors ,Source code ,Computer science ,Deconvolution ,computer.software_genre ,Biochemistry ,Omics integration ,0302 clinical medicine ,Resource (project management) ,Structural Biology ,Medicine and Health Sciences ,Biology (General) ,Càncer ,media_common ,Cancer ,0303 health sciences ,[SDV.BIBS] Life Sciences [q-bio]/Quantitative Methods [q-bio.QM] ,DNA methylation ,Applied Mathematics ,Benchmarking ,[SDV.BIBS]Life Sciences [q-bio]/Quantitative Methods [q-bio.QM] ,Computer algorithms ,3. Good health ,Computer Science Applications ,Benchmarking platform ,030220 oncology & carcinogenesis ,Benchmark (computing) ,Algorithms ,EXPRESSION ,Cellular heterogeneity ,QH301-705.5 ,media_common.quotation_subject ,Computer applications to medicine. Medical informatics ,R858-859.7 ,Adenocarcinoma ,Machine learning ,Set (abstract data type) ,03 medical and health sciences ,Computational Deconvolution ,Humans ,Leverage (statistics) ,Algorismes computacionals ,CELL ,Molecular Biology ,030304 developmental biology ,business.industry ,Tumors classification ,Computational Biology ,Gold standard (test) ,Pancreatic Neoplasms ,Artificial intelligence ,business ,Transcriptome ,computer ,Software - Abstract
Background Quantification of tumor heterogeneity is essential to better understand cancer progression and to adapt therapeutic treatments to patient specificities. Bioinformatic tools to assess the different cell populations from single-omic datasets as bulk transcriptome or methylome samples have been recently developed, including reference-based and reference-free methods. Improved methods using multi-omic datasets are yet to be developed in the future and the community would need systematic tools to perform a comparative evaluation of these algorithms on controlled data. Results We present DECONbench, a standardized unbiased benchmarking resource, applied to the evaluation of computational methods quantifying cell-type heterogeneity in cancer. DECONbench includes gold standard simulated benchmark datasets, consisting of transcriptome and methylome profiles mimicking pancreatic adenocarcinoma molecular heterogeneity, and a set of baseline deconvolution methods (reference-free algorithms inferring cell-type proportions). DECONbench performs a systematic performance evaluation of each new methodological contribution and provides the possibility to publicly share source code and scoring. Conclusion DECONbench allows continuous submission of new methods in a user-friendly fashion, each novel contribution being automatically compared to the reference baseline methods, which enables crowdsourced benchmarking. DECONbench is designed to serve as a reference platform for the benchmarking of deconvolution methods in the evaluation of cancer heterogeneity. We believe it will contribute to leverage the benchmarking practices in the biomedical and life science communities. DECONbench is hosted on the open source Codalab competition platform. It is freely available at: https://competitions.codalab.org/competitions/27453.
- Full Text
- View/download PDF
31. The evolving reality of digital health.
- Author
-
Bit-Avragim N, Bousquet J, Cantù S, Omboni S, Ravot E, and Tunnah P
- Abstract
Myriad digital health interventions, applications, devices and technologies have, and are, being developed to help refine and personalise medicine from the patient, healthcare professional (HCP), healthcare system and industry perspectives. At a gathering of leaders in digital health, discussion included the current landscape of such digital health tools (DHTs), with specific examples from cardiology and respiratory medicine, and both the benefits and sometime downfalls of such tools. While DHTs can help patients and HCPs detect and monitor health conditions, the experts discussed how adoption of DHTs may be hampered by issues such as access to technology; data privacy and security concerns; technology integration into current healthcare systems; cost and reimbursement; and lack of guidelines and regulatory hurdles. The experts suggested solutions to such issues, including wider availability of healthcare 'booths' local to a patient; easy to understand and use phone applications; patient and HCP incentives to use DHTs and clear paths to adoption within a healthcare system. These should help with integration of DHTs into the healthcare system to aid shared decision-making and, ultimately, streamline and personalise healthcare for all., Competing Interests: The authors declared no potential conflicts of interest with respect to the research, authorship and/or publication of this article., (© The Author(s) 2024.)
- Published
- 2024
- Full Text
- View/download PDF
32. Smart FOX - Enabling Citizen-Based Donation of EHR-Standardised Data for Clinical Research in Austria.
- Author
-
Donsa K, Kreiner K, Hayn D, Rzepka A, Ovejero S, Topolnik M, Ziegl A, Pfeifer B, Neururer S, Kaltenbrunner S, Klager E, Zatloukal K, Zatloukal B, Schabetsberger T, Garcia ML, Tanjga N, and Schreier G
- Subjects
- Austria, Humans, Citizen Science, Community Participation, Electronic Health Records, Biomedical Research
- Abstract
Access to healthcare data for secondary use in clinical research is often restricted due to privacy concerns or business interests, hindering comprehensive analysis across patient pathways. The Smart FOX project seeks to address this challenge by developing concepts, methods, and tools to facilitate citizen/patient-driven donations of health data for clinical research. Leveraging the groundwork, laid by the national Electronic Health Record implementation in Austria (called ELGA), Smart FOX aims to harness structured datasets from ELGA for research purposes through an opt-in approach. With funding secured from the Austrian Research Promotion Agency, the project embarks on innovative solutions encompassing governance frameworks, community engagement, and technical infrastructure. The Smart FOX consortium, comprising key stakeholders across various healthcare-associated domains, will evaluate these efforts through demonstrators focusing on clinical registries, patient-generated data, and recruitment services. The project targets to accompany the development of future data donation infrastructure while ultimately advancing clinical research efficiency and bolstering Austria's preparedness for the European Health Data Space. This paper presents the first systematic evaluation of the technical concept and proposal for the federated system architecture of the Austrian Health Data Donation Space, which is the socio-technical goal of Smart FOX.
- Published
- 2024
- Full Text
- View/download PDF
33. Implementation of a comprehensive clinical risk management system in a university hospital.
- Author
-
Buchberger W, Schmied M, Schomaker M, Del Rio A, and Siebert U
- Subjects
- Humans, Germany, Hospitals, University, Risk Management methods
- Abstract
Background: Adverse events during hospital treatment are common and can lead to serious harm. This study reports the implementation of a comprehensive clinical risk management system in a university hospital and assesses the impact of clinical risk management on patient harms., Methods: The clinical risk management system was rolled out over a period of eight years and consisted of a training of interdisciplinary risk management teams, external and internal risk audits, and the implementation of a critical incident reporting system (CIRS). The risks identified during the audits were analyzed according to the type, severity, and implementation of preventive measures. Other key figures of the risk management system were obtained from the annual risk reports. The number of liability cases was used as primary outcome measurement., Results: Of the 1,104 risks identified during the risk audits, 56.2% were related to organization, 21.3% to documentation, 15.3% to treatment, and 7.2% to patient information and consent. The highest proportion of serious risks was found in the category organization (22.7%), the lowest in the category documentation (13.6%). Critical incident reporting identified between 241 and 370 critical incidents per year, for which in 79.5% to 83% preventive measures were implemented within twelve months. The frequency of incident reports per department correlated with the number of active risk managers and risk team meetings. Compared with the years prior to the introduction of the clinical risk management system, an average annual reduction of harms by 60.1% (95% CI: 57.1; 63.1) was observed two years after the implementation was completed. On average, the rate of harms dropped by 5% per year for each 10% increase in roll-out of the clinical risk management system (incidence rate ratio: 0.95; 95% CI: 0.93; 0.97) ., Conclusion: The results of this project demonstrate the effectiveness of clinical risk management in detecting treatment-related risks and in reducing harm to patients., (Copyright © 2023. Published by Elsevier GmbH.)
- Published
- 2024
- Full Text
- View/download PDF
34. The German Fast Track Toward Reimbursement of Digital Health Applications: Opportunities and Challenges for Manufacturers, Healthcare Providers, and People With Diabetes.
- Author
-
Schliess F, Affini Dicenzo T, Gaus N, Bourez JM, Stegbauer C, Szecsenyi J, Jacobsen M, Müller-Wieland D, Kulzer B, and Heinemann L
- Subjects
- Humans, Health Personnel, Europe, Germany, Digital Health, Diabetes Mellitus therapy
- Abstract
Background: Digital health applications (DiGA) supporting the management of diabetes are among the most commonly available digital health technologies. However, transparent quality assurance of DiGA and clinical proof of a positive healthcare effect is often missing, which creates skepticism of some stakeholders regarding the usage and reimbursement of these applications., Methods: This article reviews the recently established fast-track integration of DiGA in the German reimbursement market, with emphasis on the current impact for manufacturers, healthcare providers, and people with diabetes. The German DiGA fast track is contextualised with corresponding initiatives in Europe., Results: The option of a provisional prescription and reimbursement of DiGA while proving a positive healthcare effect in parallel may expedite the adoption of DiGA in Germany and beyond. However, hurdles for a permanent prescription and reimbursement of DiGA are high and only one of 12 that have achieved this status specifically addresses people with diabetes., Conclusion: The DiGA fast track needs to be further enhanced to cope with remaining skepticism and contribute even more to a value-based diabetes care., Competing Interests: Declaration of Conflicting InterestsThe author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: F.S. and T.A.D. are full-time employees of Profil Institut für Stoffwechselforschung GmbH. L.H. is a shareholder of Profil Institut für Stoffwechselforschung GmbH. F.S. is a member of the EIT Health Supervisory Board. J.-M.B. and N.G. are full-time employees of the EIT Health e.V. and the EIT Health Colocation Center Germany–Switzerland, respectively. F.S., T.A.-D., C.S., J.S., M.J., and D.M.-W. are part of the EIT Health-funded RealWorld4Clinic consortium.
- Published
- 2024
- Full Text
- View/download PDF
35. Evaluation of digital medical devices: How to take into account the specificities of these solutions?
- Author
-
Trancart A, Riche VP, Disset A, Camus D, Josseran A, Bécache P, Charle-Maachi C, De Place L, Denninger A, Fabiano J, Gourio C, and Vercamer V
- Subjects
- Humans, Reproducibility of Results, Europe, France, Delivery of Health Care
- Abstract
The beginning of the 21st century has seen an increasing number of digital medical devices (DMDs) arrive on the European market, bringing major benefits and changes for society. DMDs are unique in that they bring intelligence to the organisation of care, and generate and collect a wealth of real-life data with ultra-fast life cycles. They have specific requirements, particularly in terms of data security and interoperability. In France and Europe, the construction of evidence, the assessment process and evaluation methodologies with a view to purchase or reimbursement must adjust to these changes, given the specific features of these technologies. This digital leap has opened up new perspectives for healthcare, along with economic, ethical and regulatory issues. The challenge is to assess the clinical and organisational impact, reliability, safety, interoperability, efficiency and budgetary impact of DMDs in line with the requirements of new standards, guidelines and regulations. This should result in a coherent, pragmatic and proportionate evaluation, so that public decision-makers and buyers can take advantage of the potential opportunities that these digital devices offer to improve healthcare delivery. Thus, a fair and informed evaluation of DMDs would emerge, providing a solid basis to steer their inclusion into contemporary medical practices. This fundamental issue of evaluation, linked to the digital nature of these MDs, is what the round table, comprising experts from academia and/or hospitals, institutions and industry, sought to resolve. Discussions led to proposals on how DMDs should be evaluated, bearing in mind their complexity. The round table set out to identify the bottlenecks in the entire evaluation process, from the CE marking phase, compliance with French safety and interoperability requirements, through to national or local evaluation, in order to inform a purchasing policy and draw up proposals covering the entire spectrum. Ten concrete recommendations were put forward by the round table, aimed at improving the evaluation process by making it clearer and more adaptable, thus offering greater flexibility in the evaluation and decision-making stages. This well-thought-out approach is designed to facilitate a comprehensive and flexible evaluation of DMDs given the constantly evolving technological context., (Copyright © 2024. Published by Elsevier Masson SAS.)
- Published
- 2024
- Full Text
- View/download PDF
36. Évaluation des dispositifs médicaux numériques : comment prendre en compte les spécificités de ces solutions ?
- Author
-
Trancart A, Riche VP, Disset A, Camus D, Josseran A, Bécache P, Charle-Maachi C, De Place L, Denninger A, Fabiano J, Gourio C, and Vercamer V
- Published
- 2024
- Full Text
- View/download PDF
37. International practices in health technology assessment and public financing of digital health technologies: recommendations for Hungary.
- Author
-
Mezei F, Horváth K, Pálfi M, Lovas K, Ádám I, and Túri G
- Subjects
- Hungary, European Union, Financing, Government, Technology Assessment, Biomedical, Ecosystem
- Abstract
Background: Evaluating and integrating digital health technologies is a critical component of a national healthcare ecosystem in the 2020s and is expected to even increase in significance., Design: The paper gives an overview of international practices on public financing and health technology assessment of digital health technologies (DHTs) in five European Union (EU) countries and outlines recommendations for country-level action that relevant stakeholders can consider in order to support uptake of digital health solutions in Hungary. A scoping review was carried out to identify and gather country-specific classifications and international practices on the financing DHTs in five pioneering EU countries: Germany, France, Belgium, the United Kingdom and Finland., Results: Several frameworks have been developed for DHTs, however there is no single, unified framework or method for classification, evaluation, and financing of digital health technologies in European context. European countries apply different taxonomy, use different assessment domains and regulations for the reimbursement of DHTs. The Working Group of the Hungarian Health Economic Society recommends eight specific points for stakeholders, importantly taking active role in shaping common clinical evidence standards and technical quality criteria across in order for common standards to be developed in the European Union single market., Conclusion: Specificities of national healthcare contexts must be taken into account in decisions to allocate public funds to certain therapies rather than others., Competing Interests: KL was employed partly by CE Certiso Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2023 Mezei, Horváth, Pálfi, Lovas, Ádám and Túri.)
- Published
- 2023
- Full Text
- View/download PDF
38. The impact of insomnia on frailty and the hallmarks of aging.
- Author
-
Carvalhas-Almeida C, Cavadas C, and Álvaro AR
- Subjects
- Animals, Humans, Aged, Aging genetics, Sleep, Cellular Senescence, Sleep Initiation and Maintenance Disorders, Frailty epidemiology
- Abstract
Throughout the course of life, there are age-related changes in sleep. Despite these normal changes, there is a high percentage of older adults that report sleep dissatisfaction with a high pervasiveness of chronic insomnia, the most common sleep disorder worldwide, with its prevalence being expected to continuously increase due to the growing rates of aging and obesity. This can have different adverse health outcomes, especially by promoting both physical and cognitive decline, which ultimately may aggravate frailty in older adults. Moreover, age-related frailty and sleep dysfunction may have a common mechanism related to the hallmarks of cellular aging. Cellular aging was categorized into nine hallmarks, such as DNA damage, telomere attrition and epigenetic changes. In the context of geriatric and chronic insomnia research, this review aims at discussing the current evidence from both animal models and human cohorts addressing the link between chronic insomnia, the hallmarks of aging and their impact on frailty. Moreover, the most recent research about the putative effect of insomnia therapeutic approaches on hallmarks of aging will be also highlighted., (© 2022. The Author(s).)
- Published
- 2023
- Full Text
- View/download PDF
39. Frailty-the missing constraint in radiotherapy treatment planning for older adults.
- Author
-
Rodrigues ED, Gonsalves D, Teixeira L, and López E
- Subjects
- Humans, Aged, Frail Elderly, Prevalence, Free Radicals, Geriatric Assessment, Frailty epidemiology
- Abstract
Current demographic changes translate into an increased frequency of cancer in older adults. Available data show that about 45-55% of the new cancer patients will need RT treatments, with an expected increase of 20-30% in the future. To provide the best cancer care it is mandatory to assess frailty, offer appropriate curative treatments to patients and personalise them for the frail. Based on published data, the median prevalence of frailty in older population is about 42%. Recently, the free radical theory of frailty has been proposed stating that oxidative damage is more prevalent in frail patients. In parallel, RT is one of the most frequent cancer treatments offered to older adults and is a source of external free radicals. RT dose constraints correlate with toxicity rates, so we open the question whether frailty should be considered when defining these constraints. Thus, for this paper, we will highlight the importance of frailty evaluation for RT treatment decisions and outcomes., (© 2022. The Author(s), under exclusive licence to Springer Nature Switzerland AG.)
- Published
- 2022
- Full Text
- View/download PDF
40. The Role of Patients in Health Education.
- Author
-
Leggeri I, Tarrus Barberillo M, Dutarte M, Nafria Escalera B, Murphy E, Scalabrini S, Ariza-Vega P, and Carrera C
- Abstract
Competing Interests: No potential conflict of interest was reported by the author(s).
- Published
- 2022
- Full Text
- View/download PDF
41. Advancing digital health applications: priorities for innovation in real-world evidence generation.
- Author
-
Stern AD, Brönneke J, Debatin JF, Hagen J, Matthies H, Patel S, Clay I, Eskofier B, Herr A, Hoeller K, Jaksa A, Kramer DB, Kyhlstedt M, Lofgren KT, Mahendraratnam N, Muehlan H, Reif S, Riedemann L, and Goldsack JC
- Subjects
- Germany, Delivery of Health Care, Health Facilities
- Abstract
In 2019, Germany passed the Digital Healthcare Act, which, among other things, created a "Fast-Track" regulatory and reimbursement pathway for digital health applications in the German market. The pathway explicitly provides for flexibility in how researchers can present evidence for new digital products, including the use of real-world data and real-world evidence. Against this backdrop, the Digital Medicine Society and the Health Innovation Hub of the German Federal Ministry of Health convened a set of roundtable discussions to bring together international experts in evidence generation for digital medicine products. This Viewpoint highlights findings from these discussions with the aims of (1) accelerating and stimulating innovative approaches to digital medical product evaluation, and (2) promoting international harmonisation of best evidentiary practices. Advancing these topics and fostering international agreement on evaluation approaches will be vital to the safe, effective, and evidence-based deployment and acceptance of digital health applications globally., Competing Interests: Declaration of interests ADS declares that she serves as a member of the Scientific Advisory Board of HumanFirst. SP declares that he serves on the Advisory Board of the Brown-Lifespan Center of Digital Health and Clinicom. IC declares honoraria from University of Basel, ETH Zurich, and FHNW, and holds stock options in Evidation Health. BE declares funding from the DFG (German Research Foundation) Heisenberg Funding (ES434/11), DFG SFB 1483 EmpkinS; consulting fees from Adidas AG, Siemens Healthineers, Portabiles HealthCare Technologies, and Sivantos; honoraria from AbbVie Deutschland and AGAPLESION; and a patent application EP 16174268.9 (Gait Assessment), with Portabiles HealthCare Technologies. KH declares grant income from the European Innovation Council, patent WO2010105946 (A1) (Endoscope and Imaging Device), also published as DE102009013761 (A1), ES2384949 (T3), EP2323541 (A1), EP2323541 (B1), AT550982 (T); stock or stock options in Siemens Healthineers, Siemens, and BioNTech; and other financial interests in EIT Health. AJ declares honoraria from ISPOR and stock or stock options in Aetion and CVS Health. DBK declares research grants from the National Institutes of Health and the Moore Foundation and consulting income from Firefly Health. MK declares financial interests as the owner of Synergus RWE, a market access consulting company. KTL is an employee of Foundation Medicine, a wholly owned subsidiary of Roche, and declares equity interest in Roche. NM is an employee of Aetion. HMu declares research grants from the German Federal Ministry of Education and Research (GBA Research Grant [01VSF16027] 2017–2021) and the German Research Foundation (MIMI [Evaluation Study] 2018–2019). SR declares funding from the Ministry of Science, Research and Arts, State of Baden-Württemberg, Germany, and the Digital Medical Application Center. The other authors declare no competing interests., (Copyright © 2022 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
42. Integrated personalized diabetes management goes Europe: A multi-disciplinary approach to innovating type 2 diabetes care in Europe.
- Author
-
Jones A, Bardram JE, Bækgaard P, Cramer-Petersen CL, Skinner T, Vrangbæk K, Starr L, Nørgaard K, Lind N, Bechmann Christensen M, Glümer C, Wang-Sattler R, Laxy M, Brander E, Heinemann L, Heise T, Schliess F, Ladewig K, and Kownatka D
- Subjects
- Blood Glucose Self-Monitoring, Delivery of Health Care, Disease Management, Europe, Humans, Diabetes Mellitus, Type 2 diagnosis, Diabetes Mellitus, Type 2 therapy
- Abstract
Type 2 diabetes mellitus represents a multi-dimensional challenge for European and global societies alike. Building on an iterative six-step disease management process that leverages feedback loops and utilizes commodity digital tools, the PDM-ProValue study program demonstrated that integrated personalized diabetes management, or iPDM, can improve the standard of care for persons living with diabetes in a sustainable way. The novel "iPDM Goes Europe" consortium strives to advance iPDM adoption by (1) implementing the concept in a value-based healthcare setting for the treatment of persons living with type 2 diabetes, (2) providing tools to assess the patient's physical and mental health status, and (3) exploring new avenues to take advantage of emerging big data resources., (Copyright © 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
43. Next-generation ARIA care pathways for rhinitis and asthma: a model for multimorbid chronic diseases.
- Author
-
Bousquet JJ, Schünemann HJ, Togias A, Erhola M, Hellings PW, Zuberbier T, Agache I, Ansotegui IJ, Anto JM, Bachert C, Becker S, Bedolla-Barajas M, Bewick M, Bosnic-Anticevich S, Bosse I, Boulet LP, Bourrez JM, Brusselle G, Chavannes N, Costa E, Cruz AA, Czarlewski W, Fokkens WJ, Fonseca JA, Gaga M, Haahtela T, Illario M, Klimek L, Kuna P, Kvedariene V, Le LTT, Larenas-Linnemann D, Laune D, Lourenço OM, Menditto E, Mullol J, Okamoto Y, Papadopoulos N, Pham-Thi N, Picard R, Pinnock H, Roche N, Roller-Wirnsberger RE, Rolland C, Samolinski B, Sheikh A, Toppila-Salmi S, Tsiligianni I, Valiulis A, Valovirta E, Vasankari T, Ventura MT, Walker S, Williams S, Akdis CA, Annesi-Maesano I, Arnavielhe S, Basagana X, Bateman E, Bedbrook A, Bennoor KS, Benveniste S, Bergmann KC, Bialek S, Billo N, Bindslev-Jensen C, Bjermer L, Blain H, Bonini M, Bonniaud P, Bouchard J, Briedis V, Brightling CE, Brozek J, Buhl R, Buonaiuto R, Canonica GW, Cardona V, Carriazo AM, Carr W, Cartier C, Casale T, Cecchi L, Cepeda Sarabia AM, Chkhartishvili E, Chu DK, Cingi C, Colgan E, de Sousa JC, Courbis AL, Custovic A, Cvetkosvki B, D'Amato G, da Silva J, Dantas C, Dokic D, Dauvilliers Y, Dedeu A, De Feo G, Devillier P, Di Capua S, Dykewickz M, Dubakiene R, Ebisawa M, El-Gamal Y, Eller E, Emuzyte R, Farrell J, Fink-Wagner A, Fiocchi A, Fontaine JF, Gemicioğlu B, Schmid-Grendelmeir P, Gamkrelidze A, Garcia-Aymerich J, Gomez M, González Diaz S, Gotua M, Guldemond NA, Guzmán MA, Hajjam J, O'B Hourihane J, Humbert M, Iaccarino G, Ierodiakonou D, Illario M, Ivancevich JC, Joos G, Jung KS, Jutel M, Kaidashev I, Kalayci O, Kardas P, Keil T, Khaitov M, Khaltaev N, Kleine-Tebbe J, Kowalski ML, Kritikos V, Kull I, Leonardini L, Lieberman P, Lipworth B, Lodrup Carlsen KC, Loureiro CC, Louis R, Mair A, Marien G, Mahboub B, Malva J, Manning P, De Manuel Keenoy E, Marshall GD, Masjedi MR, Maspero JF, Mathieu-Dupas E, Matricardi PM, Melén E, Melo-Gomes E, Meltzer EO, Menditto E, Mercier J, Miculinic N, Mihaltan F, Milenkovic B, Moda G, Mogica-Martinez MD, Mohammad Y, Montefort S, Monti R, Morais-Almeida M, Mösges R, Münter L, Muraro A, Murray R, Naclerio R, Napoli L, Namazova-Baranova L, Neffen H, Nekam K, Neou A, Novellino E, Nyembue D, O'Hehir R, Ohta K, Okubo K, Onorato G, Ouedraogo S, Pali-Schöll I, Palkonen S, Panzner P, Park HS, Pépin JL, Pereira AM, Pfaar O, Paulino E, Phillips J, Picard R, Plavec D, Popov TA, Portejoie F, Price D, Prokopakis EP, Pugin B, Raciborski F, Rajabian-Söderlund R, Reitsma S, Rodo X, Romano A, Rosario N, Rottem M, Ryan D, Salimäki J, Sanchez-Borges MM, Sisul JC, Solé D, Somekh D, Sooronbaev T, Sova M, Spranger O, Stellato C, Stelmach R, Suppli Ulrik C, Thibaudon M, To T, Todo-Bom A, Tomazic PV, Valero AA, Valenta R, Valentin-Rostan M, van der Kleij R, Vandenplas O, Vezzani G, Viart F, Viegi G, Wallace D, Wagenmann M, Wang Y, Waserman S, Wickman M, Williams DM, Wong G, Wroczynski P, Yiallouros PK, Yorgancioglu A, Yusuf OM, Zar HJ, Zeng S, Zernotti M, Zhang L, Zhong NS, and Zidarn M
- Abstract
Background: In all societies, the burden and cost of allergic and chronic respiratory diseases are increasing rapidly. Most economies are struggling to deliver modern health care effectively. There is a need to support the transformation of the health care system into integrated care with organizational health literacy., Main Body: As an example for chronic disease care, MASK (Mobile Airways Sentinel NetworK), a new project of the ARIA (Allergic Rhinitis and its Impact on Asthma) initiative, and POLLAR (Impact of Air POLLution on Asthma and Rhinitis, EIT Health), in collaboration with professional and patient organizations in the field of allergy and airway diseases, are proposing real-life ICPs centred around the patient with rhinitis, and using mHealth to monitor environmental exposure. Three aspects of care pathways are being developed: (i) Patient participation, health literacy and self-care through technology-assisted "patient activation", (ii) Implementation of care pathways by pharmacists and (iii) Next-generation guidelines assessing the recommendations of GRADE guidelines in rhinitis and asthma using real-world evidence (RWE) obtained through mobile technology. The EU and global political agendas are of great importance in supporting the digital transformation of health and care, and MASK has been recognized by DG Santé as a Good Practice in the field of digitally-enabled, integrated, person-centred care., Conclusion: In 20 years, ARIA has considerably evolved from the first multimorbidity guideline in respiratory diseases to the digital transformation of health and care with a strong political involvement., Competing Interests: Competing interestsDr. Ansotegui reports personal fees from Mundipharma, Roxall, Sanofi, MSD, Faes Farma, Hikma, UCB, Astra Zeneca, outside the submitted work. Dr. Bosnic-Anticevich reports grants from TEVA, personal fees from TEVA, Boehringer Ingelheim, AstraZeneca, Sanofi, Mylan, outside the submitted work. Dr. Bousquet reports personal fees and others from Chiesi, Cipla, Hikma, Menarini, Mundipharma, Mylan, Novartis, Sanofi-Aventis, Takeda, Teva, Uriach, others from Kyomed, outside the submitted work. Dr. Boulet reports and Disclosure of potential conflicts of interest—last 3 years. Research grants for participation to multicentre studies, AstraZeneca, Boston Scientific, GlaxoSmithKline, Hoffman La Roche, Novartis, Ono Pharma, Sanofi, Takeda. Support for research projects introduced by the investigator AstraZeneca, Boehringer-Ingelheim, GlaxoSmithKline, Merck, Takeda. Consulting and advisory boards Astra Zeneca, Novartis, Methapharm. Royalties Co-author of “Up-To-Date” (occupational asthma). Nonprofit grants for production of educational materials AstraZeneca, Boehringer-Ingelheim, GlaxoSmithKline, Merck Frosst, Novartis. Conference fees AstraZeneca, GlaxoSmithKline, Merck, Novartis. Support for participation in conferences and meetings Novartis, Takeda. Other participations Past president and Member of the Canadian Thoracic Society Respiratory Guidelines Committee; Chair of the Board of Directors of the Global Initiative for Asthma (GINA). Chair of Global Initiative for Asthma (GINA) Guidelines Dissemination and Implementation Committee; Laval University Chair on Knowledge Transfer, Prevention and Education in Respiratory and Cardiovascular Health; Member of scientific committees for the American College of Chest Physicians, American Thoracic Society, European Respiratory Society and the World Allergy Organization; 1st Vice-President of the Global Asthma Organization “InterAsma”. Dr. Casale reports grants and non-financial support from Stallergenes, outside the submitted work. Dr. Cruz reports grants and personal fees from GlaxoSmithKline, personal fees from Boehrinher Ingelheim, AstraZeneca, Novartis, Merk, Sharp & Dohme, MEDA Pharma, EUROFARMA, Sanofi Aventis, outside the submitted work. Dr. Ebisawa reports personal fees from DBV Technologies, Mylan EPD maruho, Shionogi & CO., Ltd., Kyorin Pharmaceutical Co., Ltd., Thermofisher Diagnostics, Pfizer, Beyer, Nippon Chemifar, Takeda Pharmaceutical Co., Ltd., MSD, outside the submitted work. Dr. Ivancevich reports personal fees from Euro Farma Argentina, Faes Farma, non-financial support from Laboratorios Casasco, outside the submitted work. Dr. Haahtela reports personal fees from Mundipharma, Novartis, and Orion Pharma, outside the submitted work. Dr. Klimek reports grants and personal fees from ALK Abelló, Denmark, Novartis, Switzerland, Allergopharma, Germany, Bionorica, Germany, GSK, Great Britain, Lofarma, Italy, personal fees from MEDA, Sweden, Boehringer Ingelheim, Germany, grants from Biomay, Austria, HAL, Netherlands, LETI, Spain, Roxall, Germany, Bencard, Great Britain, outside the submitted work. V.KV has received payment for consultancy from GSK and for lectures from StallergensGreer, Berlin-CHemie and sponsorship from MYLAN for in the following professional training: ARIA masterclass in allergic rhinitis participation. Dr. Larenas Linnemann reports personal fees from GSK, Astrazeneca, MEDA, Boehringer Ingelheim, Novartis, Grunenthal, UCB, Amstrong, Siegfried, DBV Technologies, MSD, Pfizer., grants from Sanofi, Astrazeneca, Novartis, UCB, GSK, TEVA, Chiesi, Boehringer Ingelheim, outside the submitted work. Dr. Mösges reports personal fees from ALK, grants from ASIT biotech, Leti, BitopAG, Hulka, Ursapharm, Optima; personal fees from allergopharma, Nuvo, Meda, Friulchem, Hexal, Servier, Bayer, Johnson & Johnson, Klosterfrau, GSK, MSD, FAES, Stada, UCB, Allergy Therapeutics; grants and personal fees from Bencard, Stallergenes; grants, personal fees and non-financial support from Lofarma; non-financial support from Roxall, Atmos, Bionorica, Otonomy, Ferrero; personal fees and non-financial support from Novartis; Dr. Okamoto reports personal fees from Eizai Co., Ltd., Shionogi Co., Ltd., Torii Co., Ltd., GSK, MSD, Kyowa Co., Ltd., grants and personal fees from Kyorin Co., Ltd., Tiho Co., Ltd., grants from Yakuruto Co., Ltd., Yamada Bee Farm, outside the submitted work. Dr. Papadopoulos reports grants from Gerolymatos, personal fees from Hal Allergy B.V., Novartis Pharma AG, Menarini, Hal Allergy B.V., outside the submitted work. Dr. Pépin reports grants from AIR LIQUIDE FOUNDATION, AGIR à dom, ASTRA ZENECA, FISHER & PAYKEL, MUTUALIA, PHILIPS, RESMED, VITALAIRE, other from AGIR à dom, ASTRA ZENECA, BOEHRINGER INGELHEIM, JAZZ PHARMACEUTICAL, NIGHT BALANCE, PHILIPS, RESMED, SEFAM, outside the submitted work. Dr. Pfaar reports grants and personal fees from ALK-Abelló, Allergopharma Stallergenes Greer, HAL Allergy Holding B.V./HAL Allergie GmbH, Bencard Allergie GmbH/Allergy Therapeutics, Lofarma, grants from Biomay, ASIT Biotech Tools S.A, Laboratorios LETI/LETI Pharma, Anergis S.A., grants from Nuvo, Circassia, Glaxo Smith Kline, personal fees from Novartis Pharma, MEDA Pharma, Mobile Chamber Experts (a GA2LEN Partner), Pohl-Boskamp, Indoor Biotechnologies, grants from, outside the submitted work. Dr. Todo-Bom reports grants and personal fees from Novartis, Mundipharma, GSK Teva Pharma, personal fees from AstraZeneca, grants from Leti, outside the submitted work. Dr. Tsiligianni reports advisory boards from Boehringer Ingelheim and Novartis and a grant from GSK, outside the submitted work. Dr. Wallace reports and Indicates that she is the co-chair of the Joint Task Force on Practice Parameters, a task force composed of 12 members of the American Academy of Allergy, Asthma, and Immunology and the American College of Allergy, Asthma, and Immunology. Dr. Waserman reports other from CSL Behring, Shire, AstraZeneca,Teva, Meda, Merck, outside the submitted work. Dr. Zuberbier reports and Organizational affiliations: Commitee member: WHO-Initiative “Allergic Rhinitis and Its Impact on Asthma” (ARIA). Member of the Board: German Society for Allergy and Clinical Immunology (DGAKI). Head: European Centre for Allergy Research Foundation (ECARF). Secretary General: Global Allergy and Asthma European Network (GA2LEN). Member: Committee on Allergy Diagnosis and Molecular Allergology, World Allergy Organization (WAO).
- Published
- 2019
- Full Text
- View/download PDF
44. Artificial Pancreas Systems for People With Type 2 Diabetes: Conception and Design of the European CLOSE Project.
- Author
-
Schliess F, Heise T, Benesch C, Mianowska B, Stegbauer C, Broge B, Gillard P, Binkley G, Crône V, Carlier S, Delval C, Petkov A, Beck JP, Lodwig V, Gurdala M, Szecsenyi J, Rosenmöller M, Cypryk K, Mathieu C, Renard E, and Heinemann L
- Subjects
- Animals, Biomarkers, Blood Glucose metabolism, Diabetes Mellitus, Type 2 blood, Diabetes Mellitus, Type 2 diagnosis, Equipment Design, Europe, Humans, Research Design, Stakeholder Participation, Treatment Outcome, Blood Glucose drug effects, Blood Glucose Self-Monitoring instrumentation, Diabetes Mellitus, Type 2 drug therapy, Insulin Infusion Systems adverse effects, Pancreas, Artificial adverse effects
- Abstract
In the last 10 years tremendous progress has been made in the development of artificial pancreas (AP) systems for people with type 1 diabetes (T1D). The pan-European consortium CLOSE (Automated Glu cose Contro l at H ome for People with Chronic Disea se) is aiming to develop integrated AP solutions (APplus) tailored to the needs of people with type 2 diabetes (T2D). APplus comprises a product and service package complementing the AP system by obligatory training as well as home visits and telemedical consultations on demand. Outcome predictors and performance indicators shall help to identify people who could benefit most from AP usage and facilitate the measurement of AP impact in diabetes care. In a first step CLOSE will establish a scalable APplus model case working at the interface between patients, homecare service providers, and payers in France. CLOSE will then scale up APplus by pursuing geographic distribution, targeting additional audiences, and enhancing AP functionalities and interconnectedness. By being part of the European Institute of Innovation and Technology (EIT) Health public-private partnership, CLOSE is committed to the EIT "knowledge triangle" pursuing the integrated advancement of technology, education, and business creation. Putting stakeholders, education, and impact into the center of APplus advancement is considered key for achieving wide AP use in T2D care.
- Published
- 2019
- Full Text
- View/download PDF
45. POLLAR: Impact of air POLLution on Asthma and Rhinitis; a European Institute of Innovation and Technology Health (EIT Health) project.
- Author
-
Bousquet J, Anto JM, Annesi-Maesano I, Dedeu T, Dupas E, Pépin JL, Eyindanga LSZ, Arnavielhe S, Ayache J, Basagana X, Benveniste S, Venturos NC, Chan HK, Cheraitia M, Dauvilliers Y, Garcia-Aymerich J, Jullian-Desayes I, Dinesh C, Laune D, Dac JL, Nujurally I, Pau G, Picard R, Rodo X, Tamisier R, Bewick M, Billo NE, Czarlewski W, Fonseca J, Klimek L, Pfaar O, and Bourez JM
- Abstract
Allergic rhinitis (AR) is impacted by allergens and air pollution but interactions between air pollution, sleep and allergic diseases are insufficiently understood. POLLAR (Impact of air POLLution on sleep, Asthma and Rhinitis) is a project of the European Institute of Innovation and Technology (EIT Health). It will use a freely-existing application for AR monitoring that has been tested in 23 countries (the Allergy Diary , iOS and Android, 17,000 users, TLR8). The Allergy Diary will be combined with a new tool allowing queries on allergen, pollen (TLR2), sleep quality and disorders (TRL2) as well as existing longitudinal and geolocalized pollution data. Machine learning will be used to assess the relationship between air pollution, sleep and AR comparing polluted and non-polluted areas in 6 EU countries. Data generated in 2018 will be confirmed in 2019 and extended by the individual prospective assessment of pollution (portable sensor, TLR7) in AR. Sleep apnea patients will be used as a demonstrator of sleep disorder that can be modulated in terms of symptoms and severity by air pollution and AR. The geographic information system GIS will map the results. Consequences on quality of life (EQ-5D), asthma, school, work and sleep will be monitored and disseminated towards the population. The impacts of POLLAR will be (1) to propose novel care pathways integrating pollution, sleep and patients' literacy, (2) to study sleep consequences of pollution and its impact on frequent chronic diseases, (3) to improve work productivity, (4) to propose the basis for a sentinel network at the EU level for pollution and allergy, (5) to assess the societal implications of the interaction. MASK paper N°32.
- Published
- 2018
- Full Text
- View/download PDF
46. Innovation in cardiovascular disease in Europe with focus on arrhythmias: current status, opportunities, roadblocks, and the role of multiple stakeholders.
- Author
-
Prinzen FW, Dagres N, Bollmann A, Arnar DO, Bove S, Camm J, Casadei B, Kirchhof P, Kuck KH, Lumens J, Michel MC, Schwartz PJ, Van Vleymen B, Vardas P, and Hindricks G
- Subjects
- Diffusion of Innovation, Europe, Humans, Inventions, Medical Informatics trends, Organizational Innovation, Arrhythmias, Cardiac diagnosis, Arrhythmias, Cardiac therapy, Biomedical Technology methods, Biomedical Technology organization & administration, Biomedical Technology trends, Therapies, Investigational trends
- Abstract
The European Heart Rhythm Association (EHRA) held an Innovation Forum in February 2016, to consider issues around innovation. The objective of the forum was to extend the innovation debate outside of the narrow world of arrhythmia specialists and cardiology in general, and seek input from all stakeholders including regulators, strategists, technologists, industry, academia, health providers, medical societies, payers, and patients. Innovation is indispensable for a continuing improvement in health care, preferably at higher efficacy and lower costs. It requires people who have been trained in a good scientific environment, high-quality research for achieving ground breaking inventions and the certainty of return on innovation investments. In the context of cardiovascular disease, innovation can imply better risk assessment and stratification, device technology, drug development, and process design. Several areas of promising developments were identified as well as several roadblocks to innovation. To drive innovation forward all stakeholders need to play a significant role. In a globalized and extremely competitive world, the leading role of Europe in medical innovation can only be achieved through a combined and well-coordinated effort from all involved parties.
- Published
- 2018
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.